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The main aim of the study was to assess the prevalence of bronchial 
hyperresponsiveness (BHR) in the Finnish adult general population, its determinants 
and risk factors. First, the two most commonly used BHR methods, histamine 
and methacholine challenges, were compared to assess their agreement. Secondly, 
prevalence of BHR, its risk factors, and the association of active and passive smoking 
with BHR severity was studied in detail. Incident adult asthma in Helsinki over the 
11 years’ follow up was investigated. 
Subjects
For the BHR methodological comparison study 79 subjects (21-73 years) were 
included in Kemi, Finland, whereas 292 randomly selected subjects (26-66 years) 
were included for the Helsinki BHR-study. The follow up study of incident asthma 
and respiratory symptoms in 2007 included 4302 replies (participation rate 79%) 
of those, who had originally (n=6062) taken part in the FinEsS-Helsinki postal 
survey in 1996. 
Methods
In Kemi, following the postal survey, subjects were invited for clinical lung function 
tests. Bronchial challenges to methacholine and histamine were performed to each 
subject in a randomized order. In Helsinki, following the interview, skin prick tests, 
spirometry, and fractional exhaled nitric oxide (fenO) measurement, the bHr test 
with histamine was assessed. Provocative doses for histamine and methacholine 
were assessed (PD15FEV1 and PD20FEV1) and dose response ratios (DRR) were 
calculated. The highest cumulative dose for methacholine was 2.6 mg, and the 
highest non-cumulative dose for histamine was 1.6 mg. 
Histamine PD15FEV1 0.4 mg (marked BHR, BHRms) and 1.6 mg (BHR) served a 
cut-off points in the logistic regression analysis. Prevalence and incidence of asthma 
and respiratory symptoms were defined, and risk factors for bHr and incident 
asthma were determined. 
Results
The agreement of the histamine and metacholine challenge methods was 80% 
(kappa 0.45; 95% CI 0.23-0.68) in the study cohort of individuals without physician 
diagnosed asthma or chronic bronchitis. In staging the severity of BHR methods, 
the agreement was good (weighted kappa 0.64; CI 95% 0.46-0.82). 
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In Helsinki, BHR was found in 21.2% of the general adult population. Severe 
or moderate BHR (BHRms) was found in 6.2% of the subjects. FEV1 < 80% of 
predicted and airway obstruction (FEV1/ FVC < 88% of predicted) yielded over 
four-fold risk for BHR, in which the risk increased by the BHR severity. The results 
indicated that smoking (Or 4.60) plays an independent and dose-dependent role 
in markedly increased BHR even after correction of decreased lung function. Ever 
smokers comprised 69% of those with BHR, and the young age of starting to smoke 
constituted on bHr (Or 4.03). exposure to environmental tobacco smoke (ets) 
both at work and at home increased the risk for bHr (Or 6.09). Wheezing or 
asthma in childhood (Or 3.66) and female gender (Or 2.14) were also independent 
determinants for BHR in the multivariate model. Body mass index (BMI) did not 
associate with bHr. the association between fenO and bHr was dependent on 
smoking habits. Only among the non-smokers fenO leveled the bHr severity. 
In the 11 years’s follow up, 157 onsets of asthma occured, corresponding an 
incidence rate 3.7/1000/ year. Remission was 17% during that period. We observed a 
high incidence rate of allergic rhinoconjunctivitis (ARC) (16.8/1000/year), especially 
among women, and in the youngest age groups. Allergic rhinocounjuctivitis (ARC) 
doubled the risk for asthma, but living on countryside or in a farm below five years 
of age decreased the risk (Or 0.75). 
In conclusion
BHR tests with metacholine and histamine tests showed a good agreement in 
classifying severity of BHR in a population with no previous diagnosis of asthma or 
chronic bronchitis. Prevalance of BHR was 21%, and for BHRms in 6% in the general 
poplation. The main determinants for BHR were a decreased FEV1 and airway 
obstruction. Smoking and BHR were dose-dependently associated. Respiratory 
symptoms, asthma in the early childhood (<5) and female gender were associated 
with BHR, as did MEF50 < 63% predicted. 
In a longitudinal setting, our results suggested that asthma incidence in 
Finland has levelled on a plateau. Age >70 years, family history of asthma, allergic 
rhinoconjuctivitis, woman gender, and ever smoking increased the risk for adult 
onset asthma. 
Findings of this thesis suggest that quantitative assessment of BHR by different 
cut off levels provides a tool for characterization of phenotypes of airway disorders 
in epidemiological studies.
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Bronchial hyperresponsiveness (BHR) is a valid measure of the functional airway 
disturbance typically seen in asthma (Yick et al. 2012, Brannan 2010, Hargreave et 
al. 1981). BHR testing has been commonly used in epidemiological asthma studies 
(Cockcroft et al. 1977 & 1983a, Woolcock et al. 1987, Nowak et al. 1996, Burney 
et al. 1987, Norrman et al.1998, Toelle et al. 2004, Lundbäck et al. 2001), and in 
research on respiratory pathophysiology (Tiffaneau 1955, Laitinen 1974, Sterk et al. 
1985, Ward et al. 2002, Downie et al. 2007, Chanez et al. 2010, Bossé et al. 2011). 
Over the past four decades, bronchial provocation testing has been commonly 
used to diagnose or monitor asthma in Finland (Alanko 1970); usually followed by 
spirometry and bronchodilation tests. It has been feasible to include BHR testing 
in respiratory research protocols, in order to gain more information of ventilatory 
disturbances (Haahtela et al. 1991). BHR has been evaluated in the assessment of 
pathological findings from bronchial biopsies of asthmatic subjects and normal 
controls (Laitinen et al. 1985, Karjalainen et al. 2000, Lindqvist et al. 2003). 
Some of the earlier Finnish BHR-studies have focused on the development of 
methods to assess BHR (Nieminen et al. 1987, Nieminen et al. 1988, Nieminen 
1992, Sovijärvi et al. 1993) in order to improve the repeatability and accuracy of the 
BHR measures. Different ways of reporting the results of a bronchial challenge tests 
have been examined (Seppälä et al. 1990, Hedman et al. 1998) in order to feasibly 
relate the reseach data to the clinical work. However, the BHR data obtained for the 
general adult population in Finland remains lacking, and detailed epidemiological 
research to assess is warranted.
According to questionnaire studies, the prevalence of asthma was 7 % in Finland 
in 1996, but it has increased over the last decades (Pallasaho et al. 1999, Kotaniemi et 
al. 2001, Kilpeläinen et al. 2001). The prevalence of asthma is considered to be level 
with that reported in the other Nordic countries and Central Europe (Lundbäck et al. 
2001, Bakke & Gulsvik 2000; Burney et al. 1994, Chinn et al. 1997). Recent results 
from the FinEsS-Helsinki cohort, however, report a 10% prevalance of physician 
diagnosed asthma in 2006 (Kainu et al., personal communication), indicating an 
increase, which is in line with the reported observations from Italy (De Marco et 
al. 2012). 
When assessing the long term changes in the prevalence of asthma, it is necessary 
also to assess the changes in the magnitude of BHR in the general population. The 
present BHR-studies have been carried out before the exposure to environmental 
smoke (ETS) in public places and restaurants became prohibited in Finland in 
2006, thus providing valuable baseline data for longitudinal studies. This study 
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design enables the evaluation of effectiveness of the restriction of smoking exposure 
by following changes in the prevalence and incidence of BHR or respiratory 
symptoms in the general population. This work provides a much needed revision 
of this approach to lung function testing and its research, which has previously not 
received sufficient attention. 
In the presented studies, bronchial challenge tests were conducted by using 
either a dosimetric histamine or methacholine challenge method (Sovijärvi et. al. 
1993, nieminen 1992). the first clinical study presented in this thesis (study i) was 
assessed in Kemi in 1996-1997, and the third and fourth in a randomly selected 
general adult population in Helsinki, finland in 2001-2003. the findings of the 
BHR tests and the rate for incidence of asthma were evaluated from replies of postal 
surveys (Study I and II) and a clinical interview (Studies III and IV).
the purpose of this study was to assess, for the first time, the magnitude of bHr 
in Finland. Employing an epidemiological study setting, the focus was to study 
the risk factors and determinants for BHR in the general adult population, thus 
creating points of interest for more specific study projects in the area of incident 
respiratory illness or prevention of respiratory diseases. These studies are part of 
an epidemiological (FinEsS) study in which, in a longitudinal setting, follow-up 
studies are in progress in Finland, Estonia, and Sweden since 1996.
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2 Review of the literature
2 revieW oF the literature
2.1. Overview
The earliest documentations of research on BHR originates from the studies by 
Henry Salter in the 1800s, followed by studies by Alexander & Paddock (1921) and 
tiffaneau (1955) (James & ryan 1997, Yernault 1997). bHr remains, however, as 
an unexplained process in respiratory pathophysiology (Boulet 2003, Sinard et al. 
2005). 
In the 1980s, and at the beginning of the 1990s, several epidemiological studies 
reported an increased trend in the prevalence of asthma and allergy in Western 
countries (Jansen 1999). BHR testing was included in many of them, although 
mainly as a variable of lung function measurements, not as an independent outcome 
to consider. family history, allergy, and smoking had already been defined as risk 
factors for asthma (Sunyer et al. 1997, Lundbäck 1998), and the “hygiene hypothesis” 
was gradually established based on the results of ongoing epidemilogical research 
(Strachan 1989, Braun-Fahrländer et al. 1999, Remes et al. 2002). The role of 
BHR as a sign for bronchial obstruction became more investigated in the general 
population (Britton et al. 1994). The allergy-asthma pathway from early childhood 
was strongly believed to precede the incidence of asthma in early years of life, or 
later in the teenage and adult years (Kusel et al. 2007). 
During the past decade, action towards restoring the balance of innate and 
acquired immunity has been planned and executed (von Hertzen et al. 2009). 
Based on the valuable experience of the National Asthma programmes in Finland 
1994–2004, and The French plan 2002–2005, the importance of reducing the 
number of patients with severe or moderate asthma has been acknowledged in many 
European countries (European Lung White Book 2003, p.22). Due to a wide body of 
evidence simultaneously gathered from many research laboratories, countries, and 
study cohorts, it has become obvious that neither asthma nor chronic obstructive 
pulmonary disease (cOpD) are single diseases. it is hoped that this new insight 
will lead to better preventive and therapeutic strategies against the global burden 
of asthma (European Lung White Book 2003, p.21–23).
Research conducted on BHR and asthma, over recent years, has focused on the 
different type of inflammatory reactions and mediators (barnes 2008, sahlander et 
al. 2010, Marsland et al. 2011, Koarai et al. 2012). The cross linking of Th1 and Th2 
defence actions (Koya et al. 2009), functions of the altered macrophages (Byers & 
Holtzman 2011), and migration of cells in the airway smooth muscle (ASM) (Tran 
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et al. 2006) have appeared to be the hottest topics. The biological function of the 
epithelial barrier, ASM, and the interaction of these two have been of great interest 
(Siddiqui et al. 2007, Xiao et al. 2011). More trials of asthma and cOpD have 
focused on the functional disturbances of the airways, quantifying them with more 
advantagious techniques (Tgavalekos et al. 2007). The epidemiological research 
on asthma, allergy, and bHr has evolved to now focus on more specific genetic 
and epigenetic associations (Karjalainen et al. 2002b, Van Eerdewegh et al. 2002, 
Thomsen 2007, Renkonen et al. 2010, Prescott & Saffery 2011). 
2.2. BrOnchial hyperrespOnsiveness (Bhr)
2.2.1. DefinitiOns
bronchial hyperresponsiveness (bHr) is defined as a reactive narrowing of the 
airways, which leads to airflow limitation (cockcroft & Davis 2006a). bHr is 
typically seen in bronchial airway diseases, such as asthma and chronic obstructive 
bronchitis (Joos et al. 2003). It is one of the main diagnostic criteria for asthma 
(Global Initiative for Astma, GINA Guidelines, http://www.ginaasthma.org). BHR 
test results, however, depend on the cut off levels used, thus different sensitivity 
and specificity values are evident for asthma depending on the different constriction 
agents and methods used (Sovijärvi et al. 1993, Godfrey et al. 1999, Joos et al. 
2003, Koskela et al. 2003a&b). BHR is generally considered to be present when 
the histamine or metchacoline PC20 is <8-16 mg/mL or the PD20 is <3.9-7.8 µmol 
(Joos et al. 2003), and according to the methods used in Finland (Sovijärvi et al. 
1993, Nieminen 1992), histamine PD15 ≤1.6mg and methacholine pD20 ≤2.6mg, 
respectively. 
The GINA Guidelines suggest the use of BHR testing following a normal 
spirometry (http://www.ginaasthma.org) for further examinations of undiagnosed 
respiratory symptoms. The European Respiratory Society (ERS) Task Force (Joos et 
al. 2003) recommends the use of bHr testing also in titration of anti-inflammatory 
theraphy. The use of BHR testing in monitoring asthma treatment has proven to 
lead to better asthma control, fewer exacerbations, and reduced airway inflammation 
(Sont et al. 1999, van Rensen et al. 1999, Lundbäck et al. 2008), thus it is included 
as an objective lung function measure to follow up asthma in many countries. The 
Finnish Guidelines for asthma diagnosis and treatment (Astman Käypä Hoito –
suositus) consider BHR to histamine PD15 ≤0.4 mg and methacholine pD20 ≤0.600 
mg specific for a physician diagnosed asthma, and define a 30% change in the pD-
value to be a significant sign of a treatment response (sovijärvi et al. 1993, Sovijärvi 
et al. 2003). In Sweden, however, no such clinical cut off levels for asthma diagnosis 
and treatment exists. 
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The degree of increased airway reaction following a natural or induced stimulus 
may induce a different response magnitude in healthy subjects and also in those 
with an airway disease, due to intra and intersubject variation in the degree of 
BHR (Godfrey et al. 1999), which demonstrates the difficulty of using bHr testing 
in some patients or study cohorts (Hewitt 2008). The reduced cut-off levels, for 
example histamine or metchacholine < 1 mg/mL, present a high specificity and 
positive predicted value for asthma, whereas higher cut-off levels are applicable to 
exclude active asthmatic inflammation due to their high value for sensitivity (Joos 
et al. 2003, Cockcroft 2010) 
BHR has been traditionally divided into two components, the transient and the 
persistent, which provides the explanation as to why some asthmatics do not show 
bHr regardless of the findings of other lung function tests, and some asthmatics 
have BHR regardless of being treated well and being asymptomatic (Cockcroft & 
Davis 2006a, Busse 2010). The transient component of BHR is associated with 
rapid changes and reactions of the bronchus, such as exposure to allergen or 
occupational sensitizers. It is related to current asthma activity, and is typically 
the only component present in both the early stages and duration of the disease. 
The persistent component is believed to show features of airway remodelling and 
is related to both functional and structural changes in the airway due to chronic 
duration of the disease (Cockcroft & Davis 2006a, Cockcroft 2010).
2.2.2. Outlines Of Bhr measurements 
the quantification of bHr is impossible without measurements of airflow limitation 
(Yernault 1997). bronchial provocation testing is a standardized method in the 
evaluation of lung function disturbances in subjects of all ages (American Thoracic 
Society, ATS 2000). Lung function measurements at baseline, and after an induced 
bronchial challenge test, form the basic structure in assessment of BHR. After 
bronchial provocation, a broncodilatation test is performed and the reversibility 
assessed (Hughes & Pride 2001, p.220-230). 
BHR can be measured by different methods with varying criteria of abnormality 
(Rijcken et al. 1989, Joos et al. 2003, Koskela et al. 2003b). A serious attempt has 
been made to constitute the variety of the tools for measuring the BHR in the ERS 
(Joos et al. 2003) and ATS (2000) guidelines for BHR testing. Furthermore, an 
ERS Task Force for bronchial challenge testing is one of the ongoing projects on 
the international co-operation of respiratory physiologist and pulmonlogists.
In order to conduct a bronchial provocation test, a standardized method should 
be used (Sterk et al. 1993). this includes a measure to follow the induced air flow 
limitation, an established setting for the agent delivery (if not a free run test), a 
mathematical programme to calculate the final airway response, and a validated 
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way of reporting the severity of the BHR (James & Ryan 1997, Cockcroft 2010). 
The subject must be examined prior to bronchial provocation. There is a list 
of contraindications for a bronchial challenge test, including a cut off level for 
insufficient ventilatory function or a moderate level of airway obstruction (ats 
2000). A technician performs the test, although a physician needs to be present 
and available if a severe airway obstruction requires treatment. A step-wise increase 
of the provocative agent helps monitoring the state of airway reaction. After the 
bronchial provocation test, a bronchodilatation drug is given in order to resume 
baseline lung function capacity. 
A direct provocative agent, such as histamine or methacholine, acts on airway 
smooth muscle (ASM) cells, which leads to a ASM constriction and narrowing of 
the airway calibre typical for airway obstruction. Traditionally, this ASM contraction 
is believed to be due to the activation of muscarinic receptors after the release of 
acethylcholine from the cholinergic nerve plates at the neuromuscular synapsis 
of the parasympathetic axons of the vagal nerves. This approach is in contrast 
to the indirect methods, which trigger the induced ASM contraction and airway 
flow limitation by causing an excess release of inflammatory mediators, such as 
histamine, leukotrienes, and prostaglandins, which cause a cascade that determine 
in ASM constriction. (Pauwels 1988, Hughes & Pride 2001, p.221-222, Van Schoor 
et al. 2000, Anderson 2010, Busse 2010) (Table 1)
Metacholine and histamine have had an inevitable position in measuring the 
BHR (Laitinen 1974, Cockroft et al.1977, Hendrick et al. 1986). They are the most 
commonly used constrictors for BHR tests in adults (Hughes & Pride 2001, p.222). 
spirometry is most commonly used measure in the assessment of induced flow 
limitation, because it is highly reproducible (Cochrane et al. 1977), the results are 
table 1. Pharmocological and physiological agents used for inhaled provocation tests, agents for a 
direct and an undirect bronchial challenge test.
Direct Indirect
pharmacological pharmacological physical




Prostaglandins Propranolol Cold air
Airway drying




Bradykinin AMP mannitol powder
[modified from Hughes & Pride 2001, p. 222] 
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applicable to the associated clinical work. Cardiopulmonary exercise testing (CPET), 
which includes a breath by breath analysis of ventilation and intra-breath analysis 
during the exercise, is an optimal method for studying symptoms typical for exercise 
induced bronchoconstriction (EIB) among athletes as well in patients with dyspnoea 
and co-morbities (Wasserman et al. 2005). 
Delivery of the agent into the bronchus plays an important role, and is clearly 
defined for each of the methods in use. the three most commonly used methods 
for administration of inhaled pharmacological constrictor are: continuous tidal 
breathing of nebulized agent (Cockcroft et al. 1977), breath-actuated dosimeter 
(Sterk et al. 1993), and investigator-activated dosimeters, such as the Yan method 
(Yan et al.1983). 
The use of inhalation syncronized dosimetric tidal breathing methods has become 
more popular recently, because of the high reproducibility and repeatability of this 
breath actuated method (Sovijärvi et al. 1993, Jögi et al. 1999, Chinn & Schouten 
2005), in which the precise output dose of the agent can be calculated and the 
dose to the lungs evaluated (Nieminen et al. 1987). This method standardizes the 
constrictor agent’s delivery, which is known to be dependent on inhalation technique 
(Allen et al. 2005, Sinard et al. 2005, Cockcroft et al. 2005, Cockcroft & Davis 
2006b, Cockcroft 2008). 
The avoidance of deep inhalation during agent delivery has been suggested, 
as it affects the final results of the bronchial challenge test (cockcroft & Davis 
2006b, Prieto et al. 2006). Deep inhalation may cause ASM contraction in 
asthmatic subjects, while in mild asthmatics and healthy subjects the effect may 
be opposite (Skoot et al. 1995, Scichilone 2001, Brusasco et al. 1999, Kapsali et al. 
2000, Cockcroft et al. 2005). Deep inhalations also fail to cause bronchoprotective 
bronchodilatation in subjects with a significant bHr (allen et al. 2005). Way of 
breathing before or during the agent delivery alter the ASM state and bronchial tone 
in a different way in asthmatics compared to normal subjects (Sinard et al. 2005). 
Deep inhalations taken immediately after the constricting agent have been reported 
to reduce the actin-myosin cross-bridges, thus altering the ASM tone (Crimi et al. 
2008, Fredberg et al. 1997).
Differencies in the inhalation techiques might cause false negative findings with 
the dosimetric deep inhalations’ method in comparison to the two-minute tidal-
breathing method (Sundblad et al. 2000, Cockcroft et al. 2005, Burke et al. 2009). 
Allen et al. (2005) observed that a negative result was evident with the dosimetric 
method for half of the subjects with a PC20 from 2mg/mL to 16 mg/mL. In contrast, 
Cockrcoft (2008) observed that the tidal breathing method produced twice the 
response (a half of PC20) on average, of that which is reached with the dosimeter 
method. Similarly, Todd et al. (2004) showed that a dosimeter method with sub-
TLC inhalations (i.e. approximately half inspiration capacity breaths) produces 
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substantially lower PC20 values than the erJ/ ats recommended five deep breaths’ 
dosimetric method (Sterk et al. 1993, ATS 2000). 
Interpreting the results of BHR is method dependent. The most common way 
of presenting the results of the bronchial challenge test is the dose or concentration 
of the provocative agent that induces a 15% or a 20% decrease in the FEV1 value 
(PD15FEV1, PD20FEV1 or PC15FEV1, PC20FEV1, respectively). The provocative 
dose (PD) represents a quantitative value of the provocative agent calculated by 
interpolation of the results of FEV1 measurements after each increasing dose of 
the agent (Cockcroft et al. 1983b). The PD15 FEV1 value combines the information 
of bronchial hypersensitivity with the reactivity of ∆fev1–15%. the raw data of a 
change in FEV1 from the baseline (∆fev1) after each of the provocative dose level 
presents the hyperreactivity, however, only up to the maximun dose given at the 
test. These subjects, who do not reach a 15% decrease in FEV1 with the maximum 
dose assessed in the protocol, are regarded as non-responsive (no BHR). (Hughes 
& Pride 2001, p.226)
Different BHR methods are listed in table 2, where constrictor delivery, method 
of inhalation technique, and the method specific cut off level for bHr are presented.
2.3. pathOphysiOlOgy Of Bhr
2.3.1 intrODuctiOn
airway inflammation in asthma is complex and originates from a multi causal 
pathway in three different processes: acute inflammation, chronic inflammation and 
airway remodelling. Thus, several pathophysiological determinants are involved. 
(Barnes 2008, Diamant et al. 2010)
Increased ASM mass implicates in the pathogenesis of BHR and remodelling 
in patients with asthma (Borger et al. 2006, Hirst et al. 2004, Gosens et al. 2006, 
Johnson et al. 2001). ASM cell proliferation and hypertrophy, the pathways and 
mechanism, have been widely investigated during the past five years (takeda et al. 
2006, Tliba and Panettieri 2009). The mechanical changes in the bronchial tree 
and ventilation, which are typical for asthma’s chronic inflammatory process, cause 
excess ASM contraction and BHR (An et al. 2007). 
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table 2. Different BHR methods.
Method 
cut off levels
constrictor nebulizer inhalation techique
chai et al. 1975 Mch Hudson neb 0.2 ± 0.02 ml/min flow rate 6L/min; 5 breaths FRC to TLC  
DeVilbiss42 neb attached to dosimeter
cockcroft et al. 1977 Hist Wright neb, tidal breathing
ryan et al. 1981 
Hist PC20≤8mg/ mL
Hist DeVilbiss(Viasys) neb, Rosenthal-French dosimeter
hargreave et al. 1981 Mch Wright neb 0.13 ± 0.015ml/min flow rate 6L/min, Mch 0.03–32.0 mg/ml  
2 min tidal breathing 
yan et al. 1983 Hist hand operated technic; 3.1 mg/ml per inh (=0.03μmol),  
ad 3.9 μmol
yan et al. 1983 Hist DeVilbiss646 neb, Rosenhal-French dosimeter; 0.06 s nebtime; 5 x 0.3 mg/ml 
(=0.006 μmol) ad 10 mg/ml
nieminen 1992
MchPD20≤2.6mg
Mch Spira2 jet neb dosimetric, inhalation synch. tidal breathing
sovijärvi et al. 1993 
Hist PD15≤1.6mg
Hist Spira2 jet neb dosimetric, inhalation synch. tidal breathing 
sterk et al. 1993 
[ECSC _ERS 
Statement 1993]
Hist DeVilbiss646 neb (0.13 ml/min), 2 min tidal breathing 
crapo et al. 2000 
[ATS 1999]
Sterk et al. 1993: 5-breath dosimetric method 
Cockcroft et al. 1977: 2 min tidal breathing 
ref. Cockcroft 2008 Mch DeVilbiss646 neb; dosimetric, 9μL per breath, 5 FRC to TLC 
[45μL aerosol at each concentration]
ref. Cockcroft 2008 Mch Jett neb 0.13mL/min; 2 min modified tidal breathing 
[appr.90μL aerosol at each concentration]
schulze et al. 2009 Mch  APS by Viasys PD20 16mg/ml; normal Mch APS_SC >1mg
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2.3.2. rOle Of respiratOry structures, cells anD meDiatOrs in Bhr
2.3.2.1. Airway smooth muscle (ASM) and histamine 
Increased ASM in asthma, resulting from cell hyperplasia and hypertrophy, has 
been well recognized (Hirst et al. 2004, Munakata 2006). A number of factors affect 
ASM proliferation, such as growth factors, contractile agonists, extracellular matrix 
proteins, and other mediators, such as lysosomal hydrolase, tryptase, and cytokines 
(Panettieri 2008, p.89-104). These factors, in addition to oxidative stress, muscle 
stretch, a matrix upon which cells are grown, and inflammatory stimulus can trigger 
an increase in ASM proliferation in vitro (Hirst et al. 2004, Munakata, 2006). It has 
been challenging to prove these findings in vivo, however. Yick et al. (2012) have 
succeeded in demonstrating a structure-function relationship between extarcellular 
matrix in ASM and dynamics of airway function in vivo. The fractional area or 
density of ECM components in ASM between asthma patients and healthy controls 
with or without atopy showed no significant difference, but significant correlations 
between several eMc components and parameters reflecting bronchodilatation or 
bronchoconstiriction, such as metchacholine dose-response slope, existed among 
the asthmatics.
Airway smooth muscles exist around bronchi, and become more prominent 
in the smaller airways. ASM of the tertiary bronchus is typically spiral in shape, 
which makes it possible to contract both in length and diameter during expiration. 
The ASM plays a fundamental role in the bronchioles, which are less than 1mm 
in diameter, because no cartilage exists in the distal parts of the airway. The total 
crosssectional area of all bronchioles is greater than that of the rest of the conducting 
tract combined. the asM tone is responsible for airflow resistance within the lungs. 
(Burkitt et al. 1993, p.226) 
Smooth muscle is nonstriated and posesses a fusiform shape, actin, myosin, and 
intermediate filaments (desmin) form the contractile apparatus. smooth muscles are 
rich in actin relative to myosin (12:1 in smooth muscle, 2:1 in skeletal muscle), and 
tropomyosin and troponin are not found in smooth muscles. Calmodulin functions 
as a regulatory protein in smooth muscle. (Michael & Sircar 2011, p.76-80)
Excitation of smooth muscle differs from that of skeletal muscle. The axon 
innervating smooth muscle forms multiple junctions throughout the muscle. 
Neurotranmitters, ACh or norepinephrine, are released from varicosities, and 
contraction occurs finally over a muscle membrane, as in the neuromuscular junction. 
Activation occurs also via diffuse junctions in single-unit smooth muscle, in which 
the neurotransmitter-containing varicoses do not contact with any single smooth 
muscle cell. Neurotransmitter is released in close proximity to the smooth muscles, 
which leads to an activation and a contraction. All muscle cells convert ATP biological 
energy into generation of force or shortening. (Michael & Sircar 2011, p.81-90)
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ASM as part of the autonomic nervous system
It is a conventional view that the ASM is primed to contract in response to neural 
stimulation or the release of inflammatory mediators in asthma (Hughes & pride 
2001, p. 222). However, there is a complex autonomic neural system, receptors, 
neurotransmitters, reflexes, and non-neural pathways that together conduct the 
orchestra of ASM contraction (Nadel 1980, p.217-257, An et al. 2007, Racke & 
Matthiesen 2004, Pavlinkova et al. 2003, Thurmond et al. 2008, Zampeli & 
Tiligada 2009).
Acethylcholine is the transmitter of the cholinergic synapses between the pre 
and post gangliolic neurons, and acts on nicotinic or muscarinic receptors on 
postganglionic neuron. there are five types of muscarinic cholinergic receptors 
(M1-M5), all coupled via G proteins to adenylate cyclase or phospholipase C. The 
M2 and M4 receptors are found in smooth muscle. Muscarinic receptors that act 
via open K and Na channels have methacholine as an agonist and atropine as an 
antagonist. The nicotine receptors act via K-channels only. (Ganong 1993, p.85-89 
& 201-207) 
The vagus nerve, which plays an important role in BHR, carries most of the 
parasympathetic preganlionic fibers, but also carries sensoryfibers and nerves to 
skeletal muscles. parasympathetic afferent fibers bring information from the organs, 
and serve as reflex pathways. (Michael & sircar 2011, p. 98-101)
The sympathetic system, which is also referred to as the adrenergic system, 
has three types of receptors on target organs: α1receptors mediate smooth muscle 
excitation, β2 receptors mediate inhibition of smooth muscle, and β1 mediate 
excitation of the cardiac muscle. The preganglionic transmitter is Ach, and the 
post-ganglionic transmitter is norepinephirine, which binds the strongest to 
α-receptors. as an exception, ach exhibits neural excitation in the sweat glands 
and vasodilatation in the vessels of ASM. (Ganong 1993,p.85-89 & 201-207)
Activation of ASM in postganlionic receptors
Activation of postsynaptic receptors causes an excitatory postsynaptic potential 
(EPSP), or in some cases an inhibitory potential. Binding of acetylcholine to nicotinic 
receptors leads to a fast EPSP (30ms), whereas the EPSP is slower (30s) through 
muscarinic receptors. 
The cholinergic response leads to secretion of the nasopharyngeal and bronchial 
glands, and contraction of the bronchial ASM. Whereas noradrenergic impulses, 
both stimulation of the bronchial glands and ASM relaxation, are triggered via 
β-receptors. the inhibition of gland secretion only occurs via α-receptors (Michael 
& Sircar 2011, p.67). 
To conclude, parasympathetic and sympathetic receptors in the bronchioli 
contribute to the actions of ASM: the cholinergic excitation leads to ASM contraction, 
and the adrenergic excitation of β2-receptors leads to asM relaxation. (Michael & 
Sircar 2011, p.65-66)
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ASM and afferent pathways from the epithelial respiratory wall
The respiratory wall consists of sensory receptors, that mediate responses from 
physiological stimuli, such as pressure, tension, and temperature. These sensory 
receptors are nerve endings or specialized cells that convert stimuli from the 
environment, external or internal, into afferent nerve impulses, which pass in to 
the central nervous system, where they initiate voluntary or non-voluntary actions. 
The nerve endings are found in the supporting tissue, they are small in diameter, 
and typically slow in conduction rates. (Burkitt et al. 1993, p.132) Indirect stimuli, 
such as exercise or adenosine monophosphate (AMP), cause reactions via these 
neuronal pathways. Thus these stimuli are thought to be closer to the origins of 
the pathophysiology of asthma and/or spontaneous asthmatic reactions. (Hughes 
& Pride 2001, p.222). 
the vagus nerve is supplied by afferent fibers that origin in the bronchial 
epithelium. As the sensory receptors, these afferents are stimulated by both physical 
and chemical factors. the resulting neural reflex causes broncoconstriction: foreign 
particles in the trachea trigger cough, as does sulfur dioxide (sO2) and nitrogen 
dioxide (nO2). The cold air, however, has a direct effect on the ASM and leads to a 
contraction. the neural reflex does not mediate this, as it acts in response to other 
physical or chemical factors. (Michael & Sircar 2011, p. 291)
Cell respiration, ASM contraction and BHR
Respiration consists of two different but interrelated processes: cellular and 
mechanical respiration. Cell respiration is an energy process, in which high-energy 
substrates are derived from organic molecules via complex enzymatic processes. 
Mechanical respiration, in contrast, occurs in the respiratory system, and involves 
the gas exchange of inhaled and exhaled oxygen (O2) and carbon dioxide (cO2). 
(Michael & Sircar 2011, p.477-480)
Adenosine is a naturally occurring purine nucleoside. These two facts, cell 
respiration and adenosine, are linked together by adenosine metabolism (Polosa 
et al. 2002, van den Berge 2003). Asthmatics present elevated levels of adenosine 
in their respiratory airways (Driver et al. 1993). There is evidence that AMP-
induced bronchoconstriction is mediated by activation of the A2B adenosine receptor 
(Feoktistov & Biaggioni 1995). 
In optimal circumstances for energy generation, adenosine di-and triphosphates 
are converted to adenosine monophosphates, and further to high energy adenosine 
compounds (Michael & Sircar 2011, p.467). In situations such as hypoxemia, and in 
excessive cell stimulation, this process is interrupted. AMP is no longer converted 
to high-energy adenosine phosphates, but it is transported to the exterior of the cell 
and metabolised to adenosine (Polosa et al. 2002). Adenosine levels measured in 
bronchial lavage and in exhaled breath have been reported to be elevated among 
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asthmatics (Driver et al. 1993), similar to those measured after an allergen challenge 
(Mann et al. 1986).
Bronchoconstriction versus bronchodilatation
The autonomic nervous system rules bronchoconstriction in the lower the airways. 
parasympathetic, cholinergic fibers of the vagus maintain a basal contraction state 
of the ASM in the bronchi and bronchioles, which is called the bronchomotor tone. 
The bronchodilation of ASM is more complex. The non-adrenergic and non-
cholinergic (NANC) system is the principal driver of bronchodilatation. These NANC 
fibers reach the lungs via the vagus (barnes et al. 1982). Wessler and Kirkpatrick 
(2008) have explained in detail of the non-neuronal cholinergic system in humans, 
in which they explained that dysfunction of the NANC system is involved in the 
pathogenesis of different diseases. Data exists of that mucosal inflammation is 
associated with increased Ach levels, thus interferes the normal actions of those 
non-neuronal cells that carry on components of the cholinergic system, such as 
epithelial cells, submucosal glands and smooth muscle fibers (Wessler & kirkpatrick 
2001). The antimuscarinic drugs that may be used for chronic airway diseases, thus 
antagonise both the neuronal and non-neuronal acetylcholine. But, acetylcholine 
is also active on the nicotinic receptors that are found on those mentioned non-
neuronal cells, thus exhibiting Ach-dependent actions indirectly involved in mucosal 
inflammation. 
Sympathetic adrenergic control is able to cause bronchodilatation. Beta-2 
adrenoreceptors oscillate between two forms, activated and inactivated. The receptor 
is activated when it is associated with guanosine triphosphate (GTP). Following a 
replacement of gtp by guanosine diphosphate (gDp), the β2 receptor is returned 
to the inactivated, low-energy form. the β2-agonists act via binding to gtp, rather 
than inducing a conformational change in the receptor. (Johnson 2008, p.257) 
Beta2-receptor activation is associated with an increase in intracellular cAMP, 
which is a result of stimulating the ATP to cAMP conversion, which is catalysed 
by adenylate cyclase. Furthermore, cAMP levels are also related to the activity of 
phosphoriesterase isoforms, which degrade cAMP to 5’-AMP. (Michael & Sircar 
2011, p.477)
The mechanism responsible for induced ASM relaxation via cAMP is not fully 
understood. Protein kinase A activation leads to the phosphorylation of some 
proteins that regulate muscle tone (Johnson 2008, p.258). Cyclic AMP also 
triggers the inhibition of calcium ion release from intracellular sources, diminishing 
intracellular calcium stores, resulting in ASM relaxation. Inositol triphosphate IP3 
production and phospolipase C levels have been measured lower in the absence of 
the β2 receptor, and higher in the presence of high β2 receptor density, which links 
these to the cross regulation of stimulatory and inhibitory cell responses. Recent 
evidence also suggests a cross-talk of inhibitory and excitatory pathways of ASM 
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relaxation via muscarine M2 receptors and β2 receptors, whereby M2 activation 
leads to attenuated cAMP accumulation (Johnson 2008, p. 258).
Histamine
Histamine, a biogenic amine (Schnell et al. 2011), acts as a neurotransmitter and 
local mediator. It binds to histamine receptors in the respiratory epithelieum, 
consequently taking part in the inflammatory and immune responses, which are 
associated with asM functions in a complex way. Overall, histamine acts on vascular 
smooth muscle cells, which leads to vasodilation, and its actions in endothelial cells 
increase vascular permeability (Thurmond et al. 2008).
Drugs, food, and allergens cause mast cell degranulation, which subsequently 
leads to histamine release. Four histamine receptors are known: H1, H2, H3, and 
H4 (Thurmond et al. 2008). Histamine exhibits its actions via G-protein coupled 
receptors, and the four receptors exhibit their actions in different ways. H3 receptors 
are presynaptic, and they inhibit the release of histamine and other transmitters 
via G protein. H1 receptor activates phospholipase C, and H2 receptors increase 
intracellular cyclic AMP. (Ganong 1993, p. 93) The role of the histamine H4 receptor 
is under vigorous investigation, because it is known to modulate eosinophilic 
migration. The H4 receptor has been regarded as a novel target for pharmacological 
modulation of histamine-mediated signals in immune reactions (Zampeli & Tiligada 
2009). 
Histamine in action on ASM constriction 
For more than a century, histamine has been known to elicit local actions on the 
ASM, which lead to ASM constriction (Nadel 1980, p.229). 
Histamine may be inhaled to trigger ASM constriction, exhibiting its effects via 
three different pathways in the airway epithelium (Nadel 1980, p. 231). First, it has 
local effects on the asM . second, histamine triggers reflex effects via receptors in 
the airways. Third, histamine affects the efferent parasympathetic pathways. Data 
from these studies in the assessment of histamine pathways are presented by Nadel 
(1980, p. 229). Researchers were also working on BHR prior to 1971, including such 
names as Dale, Laidlaw, DeKock, Sellick, Widdicombe, Hanh, Mills, and Karczewski 
(Nadel 1980, p.217-257). 
Histamine reflex constriction
it has been suggested that the reflex effect of histamine on bronchomotor tone is 
greater when histamine is delivered to the bronchial tree instead of the pulmonary 
artery (nadel 1980, p. 222). these findings indicate that the receptors responsible 
for the constriction reflex are situated more proximally in the airways, in bronchi, 
rather than in the peripheral parts of the lower airways, i.e. in terminal bronchioles, 
alveolar ducts, or alveoli (Nadel 1980, p.222). 
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Histamine has been reported to increase activity in the efferent vagal fibers to 
bronchi. It has been substantiated that for small doses of histamine, a vagal blockade 
abolishes its bronchial effects, as does atropine, and with higher dose of histamine, 
the histamine effects are diminished (Nadel 1980, p. 231).
temperature has been suggested to effect the reflex pathways (nadel 1980, 
p. 231). no histamine reflex reactions have been observed when cervical vagus nerves 
were cooled to 7-10°C. This was regarded as the range of temperature, in which the 
reflex response to histamine was abolished but the vagal efferent pathways were 
intact. (Nadel 1980, p. 231)
2.3.2.2. Inflammatory cells
Diamant et al. (2010) has investigated cells and mediators that are involved in early 
(EAR) and late (LAR) allergic reaction, as presented in Figure 1. 
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Eosinophils in the tissues, blood, and bone marrow are increased in asthma (Kay 
2005). Eosinophils have the potential to cause damage in the airway mucosa, but no 
firm evidence that eosinophils or their products directly cause bHr in clinical asthma 
exists (van Rensen et al. 2001, Kay 2005). A study by Leckie et al. (2000), using 
an interleukin (IL)-5 monoclonal antibody, did not support the role of eosinophils 
in causing BHR. 
The major product of mast cells is tryptase, which has been reported to induce 
BHR, and to stimulate ASM responses via calcium signalling and cell proliferation 
(Berger et al. 2001). Mast cells are linked with ASM by released cytokines, such 
as iL-4, iL-13, or tumor necrosis factor (tnf)-α (Marthan et al. 2008, p. 129, 131, 
Holgate 2008)
The role of the monocyte-macrophage system in contributing to the pathology 
of asthma is less known (Holgate 2008). Macrophages are associated with 
phagocytosis, antigen presentation, and production of iL-1γ, iL-6, iL-12, and tnf-α. 
So called alternatively activated macrophages (AAMs) antagonize events of this 
classic interferon-γ pathway. aaMs respond to th2 cytokines iL-4 and iL-13, which 
are associated with the development of chronic airway disease, i.e. mucus production 
and airway hyperresponsiveness. (Byers & Holtzman 2011)
tnf-α is strongly linked to the pathogenesis of asthma, as it acts as a 
proinflammatory cytokine (Holgate 2008; Marthan et al. 2008, p.131). It has been 
shown to induce BHR and sputum production (Thomas et al. 1995), and among 
asthmatics to enhance BHR after being administered by inhalation (Thomas and 
Heywood 2002).
2.3.2.3. Respiratory epithelium
Recent studies have shown that the respiratory epithelium does not act as a 
simple barrier of physical burden, but more as a regulator of the inflammatory 
and remodeling processes (Holgate et al. 2004, Holgate 2007, Gwilt et al. 2007, 
Slats et al. 2008, Mattila et al. 2011). Results of the large-scale, genome-wide 
association study of asthma (Moffatt et al. 2010) indicate that genes that interplay 
in the communication of epithelial damage to the adaptive immune system and 
activation of airway inflammation are associated with asthma. 
Xiao et al. (2011) showed that epithelial tight junctions (TJs) are abnormal 
in asthma, thus creating a link between environmental exposure and airway 
vulnerability. Several impairments of the epitithelial barrier were found, such as 
formation of TJs, lower transepithelial electrical resistance (TER), and increased 
macromolecular permeability of the epithelium.
 the nanc-system is centrally involved in the epithelial-cell inflammatory 
response. acethylcholine (ach) is pro-inflammatory for lymphocytes and epithelial 
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cells, but anti-inflammatory for mast cells and macrophages. for monocytes, ach 
is both pro-and anti-inflammatory, and in neutrophils and esosinophils reactions 
are variable (Gwilt et al. 2007). The non-neuronal cholinergic system could be 
considered for targeted anti-muscarinic drugs which are applied to antagonize 
the effect of both neuronal and non-neuronal Ach as treatment of chronic airway 
diseases (Wessler & Kirkpatrick 2001 & 2008).
2.3.2.4. Nitric oxide (NO) as a biomarker of airway inflammation
Nitric oxide is a free radical that exhibits oxidative power in reacting rapidly with 
other molecules, such as oxygen and superoxide radicals (Török & Leuppi 2007). It 
has the potential to dilatate bronchial and vascular smooth muscle. Several cell types 
of the respiratory tract are capable of producing endogenous nO: endothelial cells 
of the epithelium and vessels, macrophages, eosinophils, and neutrophils. Bacteria 
of the saliva conduct the reduction of nitrate to nitrate, and further followed by a 
chemial reduction to nO (Marteus et al. 2005). 
according to published data, an elevated exhaled nO concentration in asthmatics 
is beyond dispute (Alving et al. 1993, Kharitonov et al. 1994, Persson et al. 1994, 
ATS/ ERS 2005, ATS 2011). However, its association with direct and indirect 
bronchial challenges is more controversial (Leuppi et al. 2002, Spallarossa et al. 
2003, Berkman et al. 2005), due to the different patterns of inflammatory cells 
involved in asthma (Laitinen & Laitinen 1994).
exhaled nO has earlier been stated as the surrogate of eosinophilic bronchial 
inflammation typical for asthma, which has been restated (alving & Malinovschi 
2010). Eosinophila is basicly induced by IL-5, however, anti IL-5 treatment has no 
effect on asthma symptoms, lung function, or BHR (Leckie et al. 2000). A recent 
statement by alving and Malinovschi (2010) suggests that exhaled nO serves as a 
marker of inhaled corticosteroid-response airway inflammation. 
 cigarette smoking decreases the levels of exhaled nO by several mechanisms, 
both exogenous and endogenous (Török & Leuppi 2007). Tobacco smoke itself is 
rich in both reactive oxygen species (oxidants, superoxide anions) and nO. the 
reactive oxygen is believed react with the nO of the airways, which diminishes 
the measurable exhaled nO levels, and is also indicated to be the reason for the 
subsequent increasing levels of the reactions’s end product, nitrate (nO3-), measured 
among smokers (Corradi et al. 1999 & 2003). Studies by others have demonstrated 
that the high cigarette smoke nO levels impact the endogenous production of nO 
via down-regulation of nO synthetase. tobacco also damages nO-producing cells, 
thus interfering the nO-process (Maziak et al. 1998, Bhowmik et al. 2005, Kanazawa 
et al. 1996, Rengasamy & Johns 1993). In a longitudinal setting, the oxidant and 
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protease burden has been shown to retain in the airways, even symptoms improve 
after smoking cessation (Louhelainen et al. 2010).
2.3.3. tOBaccO smOke
Tobacco smoke contains over 4000 chemical particles, of which 250 are know to be 
unhealthy and over 60 compounds are defined as carcinogenic (http://www.cancer.
org, http://www.stumppi.fi, http://www.suomenash.fi, Finland’s ASH-Action on 
Smoking and Health, Helakorpi 2008)
Oxidative stress also contributes significantly to smoking introduced airway 
inflammation, related to changes in lung parenchyma and smaller airways (Langen 
et al. 2003). rahman & Macnee (1998) have shown that oxidative stress is defined 
as reactive oxygen species (rOs) associated with bHr, and others have pointed out 
the association to mucus secretion and airway obstruction, in addition to activation 
of protease, and transcription of inflammatory genes (kinnula et al. 1995). 
Oxidative stress has been measured in an increased level of peroxynitrite in 
smokers and in cOpD (ito et al. 2004), and subsequently the cigarette smoke has 
also reduced the histone deacetylation (HDAC2) activity (Barnes 2009). Smoking 
leads to a decreased responsiveness in glucocorticoid treatment via decreasing the 
activity of histone deacetylation (HDAC2 ) (Ito et al. 2005): a persistant increase 
in the presence of activated chromatin exists, which associates with an increased 
transcription of inflammatory gene expression.
2.3.4.  respiratOry virus infectiOn
epidemiological asthma studies from early childhood have defined that severe 
episodic airway inflammation, which affects the rapidly growing lung and airway 
tissues, is strongly associated with the early initation of asthma (Holt et al. 2005, Stein 
2008). Rhino virus (RV) (Gern et al. 2006) and respiratory syncytial virus (RSV) 
(Stein et al. 1999), which cause severe bronchiolitis in early childhood, have been 
defined as independent risk factors for early onset asthma when studied with atopy 
(Holt et al. 2010). Immunological networks in virus-induced immunopathology 
exist, where CD8+ effector T cells have been reported to be involved. Using an 
in vivo mouse model, Grayson et al. (2007) showed how the expression of the 
high-affinity ige receptor on dendric cells links a viral infection to a chronic lung 
disease. Similarly, in a guinea pig model, Sutton et al. (2007) have reported that an 
induced RSV infection established persistent infection regardless of the host Th1/ 
Th2 background, however, the host Th1 background limited the extent of the virus 
induced bHr and airway inflammation.
33
2 Review of the literature
2.3.5. BrOchOmOtOr respOnses 
2.3.5.1. Airway smooth muscle
ASM abnormalities, particularly associated with an increase in ASM, have been 
implicated in many studies (An et al. 2007). Sudden infant death syndrome (SIDS) 
is suggested to be caused by exaggerated ASM closure (Brown & Solway 2008, p. 
61). Similarly, the ASM layer has been found to be thicker in asthmatics, compared 
to non-asthmatics (Carroll et al. 1993). Due to hyperplasia or hypertrophia, the 
increase of ASM should be associated with an increased contractile capacity, which 
has not yet been proven. Some studies have provided evidence against this theory 
(Okazawa et al. 1995), and suggested that the stiffness of the asthmatic airway wall 
is increased (Ward et al. 2001), and airway wall thickening might protect against 
excessive airway narrowing in patients with asthma (Niimi et al. 2003).
ASM tension has been proposed to be responsible for BHR (Brown & Solway 
2008, p. 61). Recently, Tsurikisawa et al. (2010) demonstrated that ASM thickness is 
inversely correlated with BHR to histamine (PC20, μg/mL), but not to acethylcholine 
(PC20, μg/mL). these results further suggested that the bHr to histamine reflected 
airway remodelling, and particularly ASM hypertrophy.
In asthmatics, ASM cells present increased maximum shortening capacity and 
velocity compared to normal individuals. This has been suggested as an explanation 
for BHR and may be related to the phosphorylation state of the activation of the 
myosin light chain kinase, to that rate of actomyosin cross-bridge activity, and 
shortening velocity. (Brown & Solway 2008, p.62). The impaired relaxation of ASM 
has been proven in animal models of BHR (Brown & Solway 2008, p. 62). Barnes 
and Pride (1983) have shown that this relaxation is prolonged in sensitized airways, 
and also that the response to β-agonist was reduced. 
2.3.5.2. Heterogenity of ventilation and small pulmonary dimensions
There has been relatively little published of the small pulmonary dimensions in 
comparison to the large body of research into the inflammatory associations of 
airway diseases in the assessment of BHR. However, BHR challenge testing, as a 
quantitative method to induce peripheral airway obstruction, has been recognized 
and commonly used in the assessment of small airway diseases (Burgel 2011). The 
small airways disease was the key topic of a European Research Seminar in 2010 
which focused on the pathophysiology of the lung periphery in health and disease 
(Sterk & Bel 2011, Burgel 2011), thus stressing the need for a better understanding 
of the functional disturbances in the assessment of airway diseases and treatment 
(Scichilone et al. 2009, Ulrik & Lange 2011).
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The heterogeneity of ventilation is a marked feature of bronchial constriction 
typical for peripheral airway disease, as demonstrated with an induced 
bronchoconstriction with methacholine (Bayat et al. 2009). It has been accepted 
that BHR testing plays an indisputable role in the development of new techniques 
for investigating pathophysiological events of the lung periphery (Niimi et al. 2000 
& 2003, Gustafsson et al. 2003, King et al. 2004, Sterk 2004, Harris et al. 2006, 
Tgavalekos et al. 2007, Chapman et al. 2012). Two high-tech modalities of functional 
imaging, single-photon emission computed tomography (SPECT) (King et al. 2010), 
and positron emission tomography (PET) (Melo et al. 2010), have been introduced 
to clinical research of airway diseases as well. These diagnostic modalities represent 
a great potential for advances in coping with lung function dynamics, i.e. increasing 
the understanding of the patchy ventilation that is typical for small airway disease 
(King et al. 2010, Usmani & Barnes 2012).
2.4. methODs tO assess Bhr 
Standardisation of the protocols for the assessment of BHR have been requested 
for some time, in order to produce more comparable results between provocation 
agents and methods (Ryan et al. 1981, Beach et al. 1993, Jögi et al. 1999, Siersted 
et al. 2000). Comparison studies of the metacholine and histamine methods have 
been published before (Juniper et al. 1978, Juniper et al. 1981, Higgins et al. 1988). 
In some former studies, however, normal subjects have not reached the determined 
cut off point for brochial hyperreactivity, or healthy subjects have been excluded 
from the analysis (Chatham et al. 1982, Beach et al. 1993, Cockcroft & Berscheid 
1983, Trigg et al. 1990). this causes difficulties in the interpretation of bHr results. 
There is some discordance between the two ATS/ ERS 1999 recommended 
protocols for administration of methacholine (Crapo et al. 2000). The two-minutes 
tidal breathing method is considered “not comparable” to the dosimetric method 
where results of bHr are defined as the pc20 and PD20 values (Burke et al. 2009, 
Cockcroft et al. 2005, Prieto et al. 2006, Allen et al. 2005). 
In early studies, the provocative agent has been delivered by continuously 
operating nebulizers (DeVilbiss, Wright) during deep tidal breathing (Cockcroft et 
al. 1977, Malo et al. 1983). This results in weakness in evaluation of the dose of the 
inhaled provocation agent (Nieminen et al. 1987, Beach et al. 1993), thus decreasing 
the level of accuracy, reproducibility, and functionality of the results. The application 
of the two-minutes tidal breathing method (Cockcroft et al. 1977) standardized some 
of the effects in inter- and intrasubjects variation, but has remained less reproducible 
in comparison to dosimetric tidal breathing methods (Chinn & Schouten 2005).
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2.4.1. reprODuciBility anD specificity Of Bhr methODs
reports have documented reproducibility, sensitivity, and specificity of both the 
histamine and metacholine challenge tests (James & Ryan 1997), but predominantly 
among asthmatics. The reproducibility of challenge tests varies but is generally 
regarded as good (Juniper et al. 1978, Eiser et al. 1981, Dehaut et al. 1983, Balzano et 
al. 1989). By dosimetric tidal breathing methods, reproducibility has been improved 
(Nieminen et al. 1987 & 1988, Sovijärvi et al. 1993), the doubling doses being ± 0.72 
and ± 0.65 (95 % ci), respectively. the specificity and sensitivity in asthma for the 
histamine challenge test, which has been employed in this study, has previously 
been reported to be remarkably high (for PD15FEV1 1.0 mg 86% specificity and 92% 
sensitivity). For the cut off level histamine PD15FEV1 0.4 mg, specificity was 100% 
and sensitivity 66% (Sovijärvi et al. 1993).
2.4.2. the Bhr methODs useD in finlanD 
In Finland, the bronchial reactivity response to methacholine is most usually 
measured by the Nieminen protocol (1992) and the response to histamine by the 
Sovijärvi et al. protocol (1993). The production of transition equations has been 
suggested, even for similar dosimetric methods, in order to be able to compare 
results (Jögi et al. 1999). At the commencement of this work, no transition equations 
were available for the present histamine and methacholine tests. 
These direct, dosimetric, short methods of histamine and methacholine 
provocation, share a common origin of a longer, 10 steps program of the metacholine 
method, in which the highest cumulative dose of metacholine, 2.3 mg, was achieved 
by inhaling increasing doses and concentrations of methacholine (Nieminen el at. 
1987). The histamine method used in the present study has has been evaluated to 
express very good day-to-day repeatability (Sovijärvi et al. 1993) and a high 0.95 
intraclass correlation coefficient, as evaluated by chinn and schouten (2005). 
Many of the lung function laboratories in Finland also provide so called “indirect 
challenge tests” (Anderson 2010), such as the free run test, inhalation of cold or 
dry air, hypercapnic challenge, or the mannitol test, in order to measure induced 
peripheral airway obstruction that is typical in asthmatic inflammation. the first 
two mentioned are in clinical use, the last mentioned used in research only. No 
comparison study of the direct and indirect methods used in the general adult 
population in Finland exist, either.
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2.5. epiDemiOlOgy Of Bhr, asthma anD allergy 
2.5.1. prevalance anD risk factOrs
Since the 1960s, research on asthma prevalence has demonstrated constantly 
increasing case numbers (Alanko 1970, Vesterinen et al. 1988, Woolcock 1991, 
Lundbäck et al. 1993, Peat et al. 1994, Kotaniemi et al. 2001, de Marco et al. 1998, 
Pallasaho et al. 2002, de Marco et al. 2012). Asthma was estimated to affect 24.6 
million people in 2009 in the United States alone, where the current prevalence of 
asthma was 8.2% in adults. (Centers for Disease Control and Prevention. http://
www.cdc.gov/nchs/data/nhsr/nhsr032.pdf, Accessed May 2012). 
In Helsinki, Finland, the self-reported prevalence of physician diagnosed asthma 
in the adult general population was 10%, based on a postal survey completed in 2006 
(Kainu et al., personal communication). This cross sectional study of the general 
population included 2449 individuals (age 20-69 years), and the study protocol was 
identical to that of a 1996 survey (Pallasaho et al. 1999). According to Kela -The Social 
insurance institution of finland, which is the provider of social security benefits 
for all residents of Finland – reports (http://www.kela.fi/in/internet/english.nsf) 
of reimbursement of asthma medications in 2006, the concomitant prevalence 
of physicians’ prescriptions for inhaled corticosteroids in the Hospital District of 
Helsinki and Uusimaa was 7.6%, in which inhabitants of all ages were included. 
The percentage for physician’s prescriptions for any asthma medication was 26.7 %.
The most common and current opinion is that the prevalance and incidence 
of respiratory symptoms have started to decrease (Ekerljung et al. 2010, Anto et 
al. 2010, Lötvall et al. 2009), indicating a possible plateau of asthma prevalence. 
In contradiction, however, recent results of a cohort of young Italians, where data 
was collected in 2007-2010 and compared to data from 1998-2000, indicated that 
the prevalence of asthma is increasing after the decrement observed in in the 90s 
(de Marco et al. 2012). This may be due to an increasing proportion of untreated 
asthmatics nowadays in Italy (de Marco et al. 2012). 
2.5.1.1. BHR 
Patel et al. (2008) suggests that the increase in respiratory symptoms from the 
1970s to the 1990s has levelled off in Western countries, but the percentages of 
wheezing symptom remain strickenly low in some developing countries, which 
indicates that great variation due to socio-geographic and environmental differencies 
exist probably in BHR as well. 
Depending of the cohort and method for BHR measurement, data from 10 
different population studies conducted in the years 1984-1992 points to a prevalence 
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table 3. A summary of population studies on BHR.
 Partly adopted from Jansen et al. 1997 and Grootendorst & Rabe 2004.
_______________________________________________________________________________ 
 
Year   Age no. subjects BHR method  
 Prevalence of BHR (%)   Asymptomatic BHR (%)  
 Prevalence of respiratory symptoms (%) 
_______________________________________________________________________________________________ 
Weiss et al. 1984 6-24 213  cold air; 9% ∆FEV1/VC   
 22%      11%                  
 40%   
Weiss et al. 1984 A 134 cold air; 9% ∆FEV1/VC   
    1+1b   
 16% 
Woolcock et al.  1987 18-88 916 Hist; PD20 ≤ 3.9 μmol or > 15% ∆FEV1n=12 
    11%   2% 
    56% 
Rijcken et al. 1987 14-64 1905 Hist; PC10 ≤ 16 mg/ml 
    25% 14% 
    29% 
Cockcroft et al. 1992 20-29 500 Hist; PC20 ≤ 8 mg/ml 
    12% 7% 
    10%  
Sears et al. 1986 9 766 MCh; PC20 < 25 mg/ml 
    23% 8% 
    27% 
Salome et al. 1987  8-11 2363 Hist; PD20 ≤ 7.8 μmol 
    18% 7% 
    34% 
Pattemore et al. 1990 7-10 2045 Hist; PD20 ≤ 7.8 μmol 
    16% 6% 
    33% 
Toelle et al. 1992  7-12 210 Hist; PD20 ≤ 7.8 μmol 
    13% 7% 
    17% 
Asher et al. 1988 6-11 2571 Hist; PD20 ≤ 7.8 μmol or > 20% ∆FEV1n=1 
    18% 9% 
    23% 
Ernst et al. 2002 p 388 MCh; PD15 ≤ 12 μmol  
    25-33% 
Riedler et al. 1998 p 613 4.5% hypertonic saline; PD15 ≤ 23ml  
    14% 
Peat et al. 1996  p 180 Hist; PD20 ≤ 3.9 μmol 
    16.% 
Burney et al. 1987 A 511 Hist; PD20 ≤ 8 μmol 
    14% 
Britton et al. 1994 A 2415 MCh; PD15 ≤ 12.25 μmol 
    13% 
Xu et al. 1997  A 2684 Hist; PC10 ≤ 8 mg/ml 
    18% 
Boulet et al. 1998 A 620 Hist; PC10 ≤8 mg/ml 
    39% 
Leynart et al. 1997 A 799 MCh; PD20 ≤ 4 mg/ml  
    34% in women and 12% in men 
_______________________________________________________________________________________________ 
Grootendorts & Rabe 2004: 1 g histamine= 3.26 mmol; 1g methacholine bromide =4.17 mmol. 
P refers to a pediatric study cohort; A refers to an adult study cohort 
Siersted et al. 2000: Mch  PC20 ≤ 8 mg/ml* correlates with Mch  PD20 ≤ 0.5 mg **  




of BHR between 11 and 35% (Jansen et al. 1997, Jansen 1999). Grootendorst and 
Rabe (2004) summarized that the prevalence of BHR among adults is 10-16% and 
in children 16-30%, referring to Pattimore et al. 1990. A Swiss general population 
study, SAPALDIA, has described the prevalence of BHR to decrease from 17-12.5 % 
in the years 1991-2011, in which the proprtion of symptomatics of those 17% were 
51% (Ackermann-Liebrich et al. 2005, Brutche et al. 2006, Curjuric et al. 2011). 
In the ERCS I studies, the BHR prevalences varied from 3 to 28% among the 16 
participating countries, with a median prevalence of 13 % (Chinn et al. 1997). 
As in many other investigations, results of multivariate regession analysis by 
Toelle et al. (2004) indicate that independent determinants for asthma symptoms in 
young adult life (at ages 23-25) are female gender (Or 1.7), having atopy (Or 2.6), 
bHr (Or 2.9), recent wheeze (2.1) and abnormal fev1/ fvc ratio in childhood (in 
age 8-10 years) (Or 3.0). the risk factor profile is dependent on the cohort, thus 
more determinants for BHR in adulthood have been presented, such as smoking, 
table 4. Prevalence of BHR in selected populations.  





Year   Age no. subjects BHR method  




Sparrow et al. 1987  A 458 MCh; PD20 < 25 mg/ml 
 30% 
Taylor et al. 1985 A 227 Hist; PC20 <16 mg/ml 
    23% 
Occupational 
Frew et al. 1992  A 733 MCh; PC20 ≤8 mg/ml 
    11% 
Storaas et al. 2007 A 197 MCh; 2minutes’ tidal, PC20 ->slope 
    21% 
Asthma 
Cockcroft et al. 1977 A 140 Hist; PC20 ≤ 8 mg/ml 
    100% 
Sunyer et al. 1995 A 214 MCh; PC20 ≤ 8 mg/ml 
    63% 
COPD 
Yan et al. 1985  A 57 Hist; PD20 ≤ 3.9 μmol 
    46% 
Kanner et al. 1994 A 5 887 MCh; PD20 ≤ 5 mg/ml 
    25% in men and 48% in women 
Tashkin et al. 1992 A 5666 MCh; PD20 ≤ 25 mg/ml 
    59% in men and 85% in women 
Skiers 
Sue-Chu et al. 2010 A 58 MCh; PD20 ≤ 1814 μg 
    40% 
    AMP; PD20 ≤ 50.5 mg 
    8% 
    Mannitol PD15 ≤ 635 mg 
    5% 
_____________________________________________________________________________________ 
 
A refers to an adult study cohort .
39
2 Review of the literature
ETS, work related causes, obesity, or increase in weight, air pollution, rhinitis, 
fenO, and other physiological or ventilatory biomarkers (Hewitt 2008 , chinn et 
al. 1997, Jansson et al. 2001 & 2006).
General population studies on BHR in the elderly are scarse, as seen from Table 3.
Since overall life expectancy has increased, (http://www.who.int/gho/publications/
world_health_statistics/EN_WHS2011_Full.pdf), such studies as presented by 
Scichilone et al. (2005), are of great value. This review included 18 BHR studies that 
had been conducted between 1983 and 2002. The results of this review suggested 
that BHR is increased by age, in which the prevalence of BHR appears to increase 
(Scichilone et al. 2005). The major determinants were reduced lung function, history 
of smoking, and atopy. The impact of female gender was suggested for further 
investigations. Another point for further investigation was the assessment of BHR 
among the elderly in defining whether the increased decline in fev1 represents the 
cause of BHR rather than being the consequence of it. 
In a study that comprised 208 individuals from Central Manchester, aged 
45-86 (Renwick & Connolly 1999), the increase in BHR was suggested to be an 
effect of baseline airway calibre. in that cohort, bHr was defined as methacholine 
PD20 ≤ 200 μg (renwick & connolly 1999), and 34% of the subjects presented bHr. 
Ten Brinke has reported (2001) BHR data for a hospital recruited cohort of 136 
severe non-smoking asthma patients. the results indicated that air flow limitation is 
common in adult patients with severe asthma, and it is associated with adult onset 
asthma (Or 3.3; 95%ci 1.2-9.0), airway hyperresponsivenss to histamine, pc20 
≤ 1mg/ml versus > 1.0 mg/ml (Or 3.9; 95%ci 1.2-13.0), and sputum eosinophils 
≥ 2% (Or 7.7;95%ci 2.4-25.1). in the cohort, a persistent air flow limitation was 
seen in 49% of subjects, in whom lung function parameters, the baseline FEV1, 
FEV1/ fvc and rv/ tLc of predicted, all three were significantly worse (p< 0.001) 
than found in the 70 other severe asthmatic patients without a persistent airflow 
limitation ten Brinke et al. 2001). 
2.5.1.2. Allergy 
atopy could be defined as a positive result from a skin prick test (spt) or a certain 
level of detected allergen specific ige. the total serum ige has commonly been used 
(ECRHS), although it is less sensitive, and is increased in non allergic conditions as 
well, such as smoking (Zetterström et al. 1981). the spt results could be defined 
as a single spt reaction ≥3 mm (bousquet et al. 2012). some studies have define 
an atopy index, in which they have calculated the ratio of positive reactions to all 
tested allergens, or a number of such positive SPT reactions, or a wheal sum, i.e. 
two times radius, of the positive reactions. Just one positive SPT result often is 
enough to define a person to be atopic or allergic.
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Kerkhof et al. (2003) demonstrated that young adults with multiple sensitization 
had the highest risk for bHr defined as metacholine pD20 ≤ 2mg/mL, whereas the 
prevalence of multisensitization in the older age group (45-70 years) was much 
lower, and did not associate with BHR. This study also demonstrated that the total 
serum IgE is associated with BHR only at older ages: in young (20-44 years), birch 
pollen and timothy grass were not associated to bHr, nor was the specific ige 
for cat (< 3.5 kU/l), but in the older subjects, the specific ige for cat (with levels 
0.70-3.5 kU/l) increased the risk for BHR 7.5-fold (96%CI 1.7-32.6). Regardless of 
the age of the subjects, levels over 3.5 kU/ l of the specific ige for house dust mite 
correlated with BHR in the young and old, but sensitization exclusively to timothy 
grass or pollen did not associate with BHR.
Boulet et al. (1997) published their study of 3371 patients with allergic symptoms, 
and grouped them into three categories according to allergic asthma, rhinitis, or 
both. the age groups for the analysis were defined as 0-5, 6-15, 16-25, 26-45, 46-
65, and ≥ 66 years, and the proportions of the patients in these age groups were 
2.5%, 27.0%, 21.6%, 34.2%, 12.6%, and 2.2%, respectively. Boulet et al. (1997) 
reported that the proportion of subjects sensitised exclusively to indoor allergens 
was 21.1%, and 5.8 % inclusively to outdoor allergens, and 53.2% exihibited allergy 
to both types of allergens. Indoor allergen sensitisation was strongly associated with 
asthma, while sensitisation to pollen only was associated with rhinitis. 
Among the elderly subjects, SPT studies of the general population are scarse 
(Skassa-Brociek et al. 1987, Schichilone et al. 2011). Participants of the Korean 
Longitudinal Study on Health and Aging comprised 854 subjects, aged ≥ 65 years, 
among whom 33% presented an allergen induced wheal greater than 0 mm (Song et 
al. 2011). In this study, older age and female sex were associated with reduced skin 
reactivity. When evaluated among those who reacted, the wheal size did not decrease 
with age and no gender effect was observed. SPT reactivity was not associated with 
BMI, smoking, atopy, or reported allergic symptoms during the last 12 months, 
including wheezing or whistling in chest, sneezing or a runny nose, or blocked nose 
without cold. (Song et al. 2011)
Results from the longitudinal general population Vlagtwedde-Vlaardingen study 
of 1965 to 1990 indicated that smoking and blood eosinophilia (≥ 275 cells/ μL) 
in individuals increases the risk to respiratory symptom development, especially 
if eosinophilia occurs among individuals with hyperresponsivenss defined as 
histaminen PC10 ≤ 8mg/ml (Or 3.67; 95% ci 1.75-7.67). eosinophilia alone did 
not significantly associate with bHr. (Jansen 1999)
The prevalence of sensitization among individuals with physician diagnosed 
asthma shows variation: in the FinEsS-Helsinki study, the prevalence was 56%, 
whereas reports of ECRHS studies present higher numbers, from 63 to 81% 
(Pallasaho et al. 2006, Leynaert et al. 2012). 
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2.5.1.3. Rhinitis
Alleric rhinitis is an IgE mediated reaction on nasal mucosa, and eosinophils are 
considered the key effector cells (Kämpe et al. 2011). Most rhinitis patients do not 
develop asthma (Nielsen et al. 2009), even though BHR to histamine is heightened 
in many individuals with allergic rhinitis (Cockcroft et al. 1992, Skiepko et al. 2011). 
Since the 1990s one of the major determinants for incident adult asthma has 
been rhinitis according to the reports of the ECRHS (Chinn et al. 2004, Torén et al. 
2004). Thus, the Global Allergy and Asthma Network of Exellence (GA2LEN) has 
developed a questionnaire in order to assess the presence of chronic rhinosinusitis 
(CRS) in a epidemiogical setting. In the very recent results, the GA2LEN survey 
(Jarvis et al. 2012) has reported the 2008-2009 prevalence of CRS among lifetime 
non-smokers in Europe to vary from 6.9% to 27.1%, in which the lowest prevalence 
is in Helsinki, Finland and Bradenburg, Germany, and the highest in Coimbra, 
Portugal (Jarvis et al. 2012). The average percentage of CRS was 10.9%. In the 
same report, the prevalence of asthma was 8.2%, and in Finland 7.8%, respectively. 
rhinitis, which was defined as a yes answer to “Do you have any nasal allergies 
or hay fever?”, was reported in all centers, on average by 30%, and in Finland by 
40%, of the subjects. 
Aronsson and colleges (2008) have reported that patients with allergic rhinitis 
and asthma symptoms manifested in greater peripheral airway obstruction 
compared to those with allergic rhinitis and BHR. The BHR method was based 
on a tidal volume triggered inhalation of methacholine with five increasing doses, 
where the maximun cumulative dose was 2000 μg. Methacholine /fev1 slope was 
used as the index of BHR. There was no diffrenece in the BHR slope between 
rhinitis with asthmatics or rhinitics with BHR, however slope for resistance in the 
frequency of 5 Hz, showed a significant increase from rhinitis patients, to rhinitis 
patients with BHR, and subsequently to patients with rhinitis and asthma (p < 0.01, 
in both respectively). These results indicate that rhinitis patients with asthma have 
a more peripherial obstruction than the rhinitis patients with or without BHR, thus 
also explaining their previous finding that asthmatics have a greater perception of 
bronchial obstruction (Aronsson et al. 2005). 
Very recent results by Skiepko et al. (2011) revealed that in patients with seasonal 
rhinitis, the airway acid-base equilibrium and nitrogen metabolite concentration in 
EBC may serve as a new area for research. They found that that BHR associated with 
increased nitrite and fractional exhaled nitric oxide (fenO), and with decreased pH, 
which links with earlier observations of the conversion of endogenous nitrite to nitric 
oxide via acidification of the airways reported by Hunt et al. (2000). Thus, Skiepko 
et al. (2011) have hypothesized that measurement of the acid- base equilibrium and 
pH-dependent nitrite production leading to BHR would serve as a better diagnostic 
tool than the more commonly used fenO. 
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2.5.1.4. Smoking
Recent reports on Finnish smoking habits describe a decreasing trend in smoking 
in all age groups, both in men and women (Kinnula et al. 2011). The government 
policy of Finland has aimed to achieve a tobacco-free Finland by 2040, which means 
policies and regulatory actions in marketing and supply of tobacco products in 
retail sale facilities, especially targeted to teenage customers. These actions support 
the Finnish aim of a –10% annual decrement in daily smoking. (http://www.
savutonsuomi.fi/en.php). 
Exposure to environmental tobacco smoke has been regulated since 1995 in 
Finland when smoking in public places and at work become prohibited (Pietinalho 
et al. 2009). Although, four years after, of the non-smokers, 8% in men and 3 % 
in women reported that they were daily forced to work exposed to tobacco smoke, 
in which the figures for the smokers were 37% and 17%, respectively. (Helakorpi 
2008, Helakorpi et al. 2008, http://www.savutonsuomi.fi/en.php). 
In 2001, Janson et al. reported the effect of passive smoking on respiratory health 
and lung function. This European Community Respiratory Health Survey I (ECRHS) 
(Burney et al. 1994) was a cross sectional study of 36 centers in Europe, in which 
Finland was not represented. Between 1990 and 1994, the reported prevalance of 
passive smoking varied between 22% and 76%, being lowest in Uppsala Sweden 
(Blanc et al. 1999). Passive smoking was associated with BHR, which was not the 
case with other lung function measurements. 
A 2006 follow up study by the ECRHS on smoking and passive smoking (Janson 
et al. 2006) indicated that active and passive smoking was reduced in all age groups 
for each 10 years followed, in all centers except in Tartu. The prevalence for quitting 
smoking was higher in men than women. Current smoking rates for the countries 
included in the 2006 report demonstrated a great variation in the smoking rates, in 
which the hightest rate for current smoking was reported in Albacete, Spain (47%), 
and the lowest in Uppsala, Sweden (14%). 
Exposure to tobacco smoke has been associated with increased BHR in several 
studies (Janson et al. 2001, Chinn et al. 2005), and there have been similar findings 
for asthma and cOpD (grootendorst & rabe 2004) in a study of healthy men, 
smokers displayed twice as high BHR rates as those who had never smoked (59% 
versus 23%) (Sparrow et al. 1987). (Table 4) In the setting of a longitudinal study, 
Hospers and colleges (2000) reported a correlation between increased mortality 
from cOpD and the severity of hyperresponsiveness, and this also held true for 
those who had never smoked. In the assessment of risk factors for BHR, ETS is 
often considered as a confounder. However, it is difficult to quantify the magnitude 
of ETS (Hewitt 2008). 
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2.5.1.5. Obesity 
During the past decades, both asthma and obesity have increased in prevalence 
worldwide (WHO consultation 2000, boulet 2008). in obese women, the risk for 
asthma has been reported to be over two fold in comparison to the normal weight 
controls (Chen et al. 2005). The asthma incidence has been related to pre-existing 
obesity (Beuther & Sutherland 2007). The Nurse’s Health Study, that comprised 85 
911 women, concluded that the weight gain plays an important role in the incident 
asthma, also in respect to asthma severity (Camargo et al. 1999). 
BHR studies in obesity are scarce, but increasing in number (Tantisera & Weiss 
2001, Aaron 2008, Dixon et al. 2010). The recent results of the 11 years’s follow up 
in the SAPALDIA study suggests that baseline BMI value is not associated with BHR, 
but the change in the reactivity slope is positively associated with BMI (Curjuric 
et al. 2011). The review by Shore (2010) summarizes 16 BHR studies on obesity 
in adults and in children. In four of the eight adult studies, a positive correlation 
existed, and in three studies no effect existed. Of the eight studies in children, five 
studies found a positive association in BHR with BMI. 
2.5.2. inciDence Of respiratOry symptOms anD asthma
self-reported wheeze has fairly good specificity and sensitivity for bHr both in 
adults and children (Patel et al. 2008, Burney et al. 1989, Shaw et al. 1995). These 
two features of respiratory disorders often co-exist, although high wheezing rates 
might indirectly indicate undiagnosed asthma in some patients (Patel et al. 2008), 
and only a minority of those individuals with physician diagnosed asthma report 
wheezing (Court et al. 2002). 
The role of BHR in context to asthma and respiratory symptoms might differ 
in between age groups (Kurukulaaratchy et al. 2003, Vonk et al. 2004, Riiser et 
al. 2012). The onset of BHR is uncommon during adolescence, but those 8-12 
years-old children who have BHR carry an approximately four-fold higher risk for 
persistant wheezing (Xuan et al. 2002), and later for relapse or onset asthma in 
adulthood. Some children grow out of BHR (Riiser et al. 2012), and the severity of 
BHR commonly decreases through adolescence, as reported by the Environment 
and childhood asthma study from Oslo. in this norwegian birth cohort study, only 
in 8% of the studied BHR increased from age 10 to 16 years. 
Based on a 30-years follow up of asthmatic children (Vonk et al. 2004), 22% of 
the studied showed a complete remission in by the age of 32-42 years. Of those in 
clinical remission, however, 57% presented BHR and/or low function (Vonk et al. 
2004). Curjuric at al. (2011) reported that in the Swiss general adult population study 
(SAPALDIA), BHR persisted in 47% of individuals aged 29-72 years, whereas 7% of 
the normoreactive individuals became hyperreactive during the 11-year follow up. 
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2.5.2.1. Incidence rates for asthma
Adjusted incident rates for asthma per 1000 person years
Recent updates from Europen countries present that incident asthma has levelled 
off (European Lung White Book 2003, p.16-25), as is also found in other Western 
countries. Different labelling of obstructive diseases is common in different societies 
(Pallasaho et al. 2005), thus warranting the employment of some harmonized 
diagnostic criteria for comparison. (European Lung White Book 2003, GINA 
Guideline)
Rates for incident asthma are higher in women, as presented in Table 5. The 
rate for incidence of asthma is also reported higher when when older age groups 
are included in the cohort (Huurre et al. 2004). In respect to age trend analysis, 
these are in accordance with the other Finnish study (Huovinen et al. 1999), which 
reported a higher cumulative incidence over the 15 year’s follow up for men (3.2%) 
and for women (4.0%) of the 50-60 years age-group in 1990 in comparison to the 
younger age-groups of 30-40 and 50-60 years. 
2.5.2.2. Determinants for incident asthma
Atopy explains only a proportion of new-onset adult asthma (Leynaert et al. 2012) 
in comparison to pediatric asthma studies, in which a positive skin prick test is 
commonly reported as the main risk factor (Or 9.3) (rönmark et al. 2001). More 
table 5.  The incident rates for asthma per 1000 persons year_1 in men and women. 
men women total incidence per 1000 persons year_1
Huovinen et al. 1999 1.5 1.7 1.6
Huurre et al. 2004 2.1
Lundbäck et al. 2001* 1.7 2.9 2.3








Ekerljung et al. 2010* 1.9 2.8 2.4
Anto et al. 2010 4.5
*adjusted incident rates 
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than half of adult onset asthma cases have been recently reported to be non-allergic 
(Anto et al. 2010). Non-allergic asthma is understood to be poorly recognised, 
especially in women for whom more than 60% of new-onset asthma has been 
reported to be non-atopic (Leynaert et al. 2012). 
The remission in childhood asthma is reported to be as high as 10% for a one-year 
follow-up period in 7-8 year old Swedish children, i.e. higher than the remission in 
adult onset asthma, in which the remission rate is much lower, from 5 to 15% during 
a ten-year follow-up period (Rönmark et al. 1999 & 2001 & 2007, Ekerljung et al. 
2008). Family history of asthma is beyond dispute to be a constant determinant for 
incident asthma in all ages (Rönmark et al. 2001, Hedlund et al. 2006, Anto et al. 
2010), thus heredity plays a significant role in the pathophysiological control of the 
onset of respiratory diseases (Prescott & Nowak-Wegrzyn 2011, Holt et al. 2005).
The outcome of childhood asthma at age 32-42 was studied by Vonk et al. 
(2004). Of those allergic asthmatic children (n=119), 30% were in clinical remission 
as adults BHR was the only sign of abnormality in 4% of the studied, where as 
bHr together with fev1 ≤ 90% of predicted constituted 11%. On the other hand, 
of those individuals with persistent symptoms (15%), symptoms were the only sign 
of abnormality for 3%, but symptoms exhibited together with BHR and FEV1 ≤ 90% 
of predicted for 12%. in this study, bHr was defined as histamine pc10 ≤ 16mg/
ml, a value comparable with PC20 8mg/ml in the 2 minutes inhalation method 
with Hargreave (Vonk 2004). 
In a Finnish birth cohort study (1967, n=2269) asthma incidence was evaluated 
from birth to young adulthood (Huurre et al. 2004). The results indicated that boys 
to have a higher incidence rate than girls, whereas from 17 to 22 years this was 
reversed, and in early adulthood (23-32 years) incidence rates for both sexes were 
equal, 2.1 /1000/ year. In the FinEsS-Stockholm study, the incidence rate for women 
was higher than in men, and in most of the adult studies this has been true for all 
age groups (Lundbäck et al. 2001, Torén et al. 2004). In the FinEsS-Stockholm 
study, however, the results of the univariate analysis for adjusted incident asthma 
and of the multivariate analyses no longer showed this gender effect. 
Longitudinal data suggest that low socio-economic status associates with incident 
asthma (Beckett et al. 2001, Eagan et al. 2004, Hedlund et al. 2006, Ekerljung et 
al. 2010). After correction for age, gender, family history of asthma, smoking habits, 
and occupational exposure to dust gases or fumes, Hedlund et al. (2006) reported 
that the manual-worker industry was at risk for development of asthma by an Or 
1.7 (95%CI 1.0-2.7). A work-related excess of asthma incidence was found in a 
Finnish study that included over 49 000 employee, aged 25-59 years during the 
follow up years of 1986-1998. It showed that over a hundred different occupations 
are associated with asthma, but typically in the majority such occupations in which 
different kinds of uncleanness exists (Karjalainen et al. 2002a). These results indicate 
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that asthma is evidently not a disease of middle and upper socio-economic classes, 
as may have been thought during the most popular years of the hygiene hypothesis. 
The evidence from numerous epidemiological studies has convinced that rhinitis 
is one of the main risk factors for incident asthma (Håkansson et al. 2011), thus 
playing an important role in context to respiratory symptoms, asthma diagnosis 
and treatment strategies (ARIA, Allergic Rhinitis and its Impact on Asthma 2007. 
http://www.whiar.org/). In a large Swedish population-based case-control study 
(EnvironMent and Asthma in P-county, MAP-study) of 15 813 subjects included, 
showed that non-infectious rhinitis and smoking increased the risk for adult-onset 
asthma, especially among the non-atopic subjects (Torén et al. 2002). 
BHR independently increased the risk for incident asthma and respiratory 
symptoms, as it is associated with an increased decline in the annual lung function 
(Brutsche et al. 2006, Boutet et al. 2007). Increased BHR is seen even in the absence 
of symptoms for bronchial asthma, especially during the pollen season (Skiepko 
et al. 2011), and this group of subjects have been suggested to have an increased 
risk for asthma later in life (Guerra et al. 2002). The causality and pathways from 
an upper airway disease to the development of a lower airway disease in certain 
individuals is not yet fully elucidated (Guerra et al. 2002, Bousquet et al. 2008). 
The ARIA (Allergic Rhinitis and its Impact on Asthma) and GA(2)LEN studies have 
put great effort into organising large-scale international studies to address these 
issues (Baena-Cagnani et al. 2008, Bousquet et al. 2009). 
2.5.2.3. Asymptomatic and symptomatic BHR 
The proportion of asymptomatic BHR in population studies has been reported 
to comprise from 2 to 14% of BHR cases, as reported by Jansen et al. (1997). In 
longitudinal asthma studies conducted in 1992-1994, BHR has been reported to 
preceed the incidence of respiratory symptoms or incidence of asthma (Peat et 
al. 1993), but opposite findings have also been suggested (de gooijer et al. 1993). 
Désirée Jansen from the Netherlands has published her thesis entitled 
“Symptomatic and asymptomatic airway hyperresponsiveness: epidemiological 
and pathological studies”, in 1999. The results indicated that various parameters 
of lung function, such as a lower pre-challenge level of FEV1 % predicted or FEV1 % 
VC, a lower maximally attained level of FEV1 % predicted between the ages of 20 
and 25, and a faster preceding decline in FEV1, were associated with AHR. Lower 
pre-challenge levels of lung functions, of % predicted, associated with the presence 
of respiratory symptoms, but only in subjects with AHR. (Jansen et al. 1999b)
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3  aiMs oF the study
1. To study the agreement of methacholine and histamine methods in the 
assessment of BHR among subjects without physician diagnosed asthma 
or chronic bronchitis.
2. to define the prevalence of bHr in subjects without physician diagnosed 
asthma or chronic bronchitis in the general population in Kemi.
3. To determine the prevalence of BHR in the general adult population in 
Helsinki. 
4. To assess the determinants and risk factors for BHR in the general population 
in Helsinki. 
5. To investigate the association of smoking exposure with BHR severity. 
6. To evaluate the determinants for BHR in terms of two cut off levels, BHRms 
and BHR, (histamine PD15fev1 ≤ 0.4 mg and bHr ≤ 1.6 mg, respectively).
7. to study the association of exhaled nitric oxide (fenO) with bHr.
8. To assess incidence of asthma and its risk factors in FinEsS-Helsinki by the 
replies of two postal surveys 11 year’s apart.
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4 Material and Methods
In the county of Lapland in northern Finland (Kemi), 79 subjects were included in a 
bronchial challenge study with methacholine and histamine in the years 1997-1998. 
In Helsinki, 6062 subjects took part in a postal survey in 1996, and 292 of 
them participated in the bronchial challenge studies in 2001-2003. Later, 4302 
subjects of those 6062 subjects were participating in a follow-up postal survey in 
2007. a flow chart demonstrating the sampling for the cohorts studied in Helsinki 
are given in Figure 2.
The studies were approved by the ethics committee of Länsi-Pohja Central 
Hospital Ethics Committee in Kemi and the ethics committee of Helsinki University 
Hospital. All patients gave the written informed consent. 
4.1. suBjects anD stuDy Design
4.1.1. suBjects Of the kemi cOhOrt (stuDy i)
The FinEsS studies in North Finland (Kemi) started in 1995. The postal survey 
comprised 7937 subjects (age 20-69 years), and the participation rate was 84%. Of 
the responders of the southern part of the study area (n=3420), a random sample 
of 959 subjects were invited to clinical studies performed in 1995-1996. (Kotaniemi 
et al. 2001)
For Study I, 79 adult volunteers were included. All of them had taken part in 
the FinEsS postal questionnaire survey in North Finland in 1996 (Kotaniemi et al. 
2001). The subjects were randomly selected from a group of the FinEsS participants 
who did not have asthma or chronic bronchitis and who were living in Kemi or its 
surroundings. they had answered “nO” to the following questions: 1)“Have you now, 
or have you had, any of the following diseases: a) asthma? b) chronic bronchitis or 
emphysema?”; 2) “Have you been diagnosed as having asthma by a physician?”; 
3)“Have you been diagnosed as having chronic bronchitis or emphysema by a 
physician?”. The age range of the studied subjects was 21-73 years (47% women). 
Their demographic data are presented in Table 6a. 
4.1.2. suBjects Of the helsinki cOhOrts (stuDies iii-iv anD ii)
the flow chart of the cohorts of the finess-Helsinki studies is presented in figure 2.
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Figure 2. Flow chart for the study cohort in Helsinki.
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table 6a. Demographic data of the subjects studied in Kemi for BHR, n=79. 
Men (n=42) Women (n=37) total (n=79)
mean±SD (range) mean±SD (range) mean±SD (range)
age (years) 50.4 ± 15.7 48.5 ± 12.7 49.5 ± 14.3
(21–71) (22-73) (21-73)
height (m) 174.3 ± 5.59 162.9 ± 6.86 1.69 ± 8.4
  (1.61-1.86) (1.46-1.74)  (1.46-1.86)
Weight (kg) 80.0 ± 12.6 70.6 ± 13.8 75.6 ± 14.0
  (43-110)  (48-105)  (43-110)
Body mass index 
(kg/m2)
26.8 ± 3.1 26.4 ± 5.2 26.6 ± 4.2
 (21.3-32.2) (19.7-42.2)  (19.7-42.2)
spirometry FEV1 [L] 3.40 ± 0.68 2.56 ± 0.48 3.01 ± 0.73 
FEV1 of predicted [%] # 96.5 (77.5-119.5) 92.8 (77.4-118.5) 94.8 (77.4-119.5)
FVC [L] 4.52 ± 0.95 3.31 ± 0.58 3.95 ± 1.00 
FVC of predicted [%] # 98.8 (77.3-122.6) 97.4 (78.2-124.0) 98.2 (77.3-124.0)
FEV1/FVC [%] 72.7 ± 7.4 74.0 ± 7.1 73.3 ± 7.2 
FEV1/FVC of predicted [%] # 97.5 (68.1-123.9) 94.3 (75.8-116.7) 96.0 (68.1-123.9)
n (%) n (%) n (%)
smoking history non-smokers n(%) 16 (38.1) 23 (62.2) 39 (49.4)
ex-smokers n(%) 13 (31.0) 3 (8.1) 16 (20.3)
smokers n(%) 13 (31.0) 11 (29.7) 24 (30.4)
Values are given as mean ± SD, and in values of the predicted [%] # as mean and range. Predicted 
values according to Viljanen et al. (1982). 
4.1.2.1. BHR studies (Studies III–IV)
The population for the FinEsS I postal survey (n=8000) was randomly selected 
from the Finnish population register (Väestökeskus) and designed to correspond 
to the general population living in Helsinki with respect to age and gender. The 
participation rate of the finess i study was 76% (n=6062). Of the participants, 1200 
were randomly invited to the FinEsS II clinical study, and half of those (n=600) 
were randomly selected to take part in the BHR study. The participation rate for the 
FinEsS II clinical study was 54% (n=643), and for the BHR study 45.4% (n=292). 
The age-range of the studied subjects was 26-66 years. Their baseline FEV1 
varied between 60-136% of predicted (mean 94%) (Viljanen et al. 1982). Physician 
diagnosed asthma was reported by 6.2% (n=18) of the subjects, and the historical 
use of asthma medication was reported by 17.8% (n=52) and during the last 12 
months by 7.5% (n=22). The demographic data are presented in Table 6b.
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table 6b. Demographic data of the subjects of the Helsinki cohort studied for BHR, n=292. 
Men (n=123) Women (n=169) total (n=292)
mean±SD (range) mean±SD (range) mean±SD (range)
age (years) 45.2 ± 9.5 (28-65) 47.3 ± 10.6 (26-66) 46.4 ± 10.2 (26-66)
height (m) 1.74 ± 0.06 (1.61-1.86) 1.63 ± 0.07 (1.46-1.74) 1.69 ± 0.08 (1.46-1.86)
Weight (kg) 80.0 ± 12.6 (43-110) 70.6 ± 13.8 (48-105) 75.6 ± 14.0 (43-110)
spirometry FEV1 [L] 4.06 ± 0.70 (2.35-5.90) 2.87 ± 0.51 (1.71-4.50) 3.37 ± 0.84 (1.71-5.90) 
FEV1 of predicted 
[%] #
94 ± 12 (62-127) 94 ± 12 (71-129) 94 ± 12 (62-129)
FVC [L] 5.28 ± 0.82 (3.09-8.03) 3.65 ± 0.61 (2.15-5.39) 4.34 ± 1.07 (2.15-8.03) 
FVC of predicted 
[%] #
99 ± 11 (67-127) 99 ± 12 (72-145) 99 ± 12 (67-145)
FEV1/FVC [%] 77 ± 6 78 ± 6 78 ± 6 
FEV1/FVC of 
predicted [%] #
95 ± 7 (71-113) 95 ± 6 (80-115) 95 ± 7 (71-115)
MEF50 [L/ s] 4.43 ± 1.33 (1.40-8.11) 3.37 ± 0.98 (1.41-6.33) 3.82 ± 1.26 (1.40-8.11)
MEF50 of predicted 
[%] #
82 ± 24 (30-147) 77 ± 20 (39-137) 79 ± 22 (30-147)
Bronchodilatation 
from baseline, ∆FEV1 
[%]
3.1 ± 3.5 (-4-21) 2.0 ± 2.9 (-5-15) 2.4 ± 3.2 (-5-21)
exhaled nitric 
oxide (ppb) ¤






smoking pack years 10.30 ± 12.57 (0-47) 7.21 ± 10.18 (0-39) 8.51 ± 11.33 (0-47)
n (%) n (%) n (%)
smoking history non-smokers n(%) 47 (38.2) 74 (43.8) 121 (41.4) 
ex-smokers n(%) 30 (24.4) 45 (26.6) 75 (25.7 )
smokers n(%) 46 (37.4) 50 (29.6) 96 (32.9)
ets ETS ever§ 84 (68.3) 131 (77.5) 215 (73.6)
ETS both at work 
and at home 
49 (39.8) 65 (38.5) 114 (39.0)
All values given as mean ±SD (range). Lung function values of the spirometry are also presented 
in values of the predicted [%], # as mean ±SD and range (n=291). Predicted values according to 
Viljanen et al. (1982). ¤ Exhaled nitric oxide (FENO), obtained from 277 subjects (men n=116, n=161 
women), flow rate used 50ml/s. § at work and/ or at home.
52
4.1.2.1. Incidence of asthma (Study II) 
A follow-up study of the original FinEsS-Helsinki study cohort (n=6962) was 
performed in 2007 for the assessment of the incidence of asthma and respiratory 
symptoms. For this new postal survey (Appendix I and II) 5484 subjects were traced, 
and 4302 replies were obtained (participation rate 79%). Of the 578 subjects who 
were lost from the follow-up, 336 were dead, 8 were living abroad, 64 were traced 
without access to address, and 170 could not be traced. The demographic data of 
the cohort obtained is presented in Table 6c.
4.2. methODs
4.2.1. lung functiOn measurements
4.2.1.1. Spirometry in Kemi (Study I)
The number of completed ventilatory function measurements was 683 (Kotaniemi et 
al. 2001&2005). before the challenge tests a flow-volume spirometry with a vmax22 
spirometer (sensorMedics corporation, Yorba Linda, ca, Usa) was performed 
according to ATS criteria (1994). A nose clip was used.
table 6c. Demographic data of the subjects in Helsinki participated in the postal survey in 2007, 
n=4302.
Men (n=1745) Women (n=2557) total (n=4302)
mean±SD (range) mean±SD (range) mean±SD (range)
age (years) 53.5 ± 12.7 53.1 ± 13.1 53.4 ± 12.9
(31–80) (31–80) (31–80)
n (%) n (%) n (%)
smoking history non-smokers n(%) 681 (39) 1381 (54) 2062 (48)
ex-smokers n(%) 593 (34) 639 (25) 1232 (29)
smokers n(%) 471 (27) 537 (21) 1008 (23)
physician diagnosed asthma 136 (7.8) 270 (10.6) 406 (9.4)
asthma medication 128 (7.3) 292 (11.4) 420 (9.8)
allergic rhinoconjunctivitis 630 (36.1) 1128 (44.1) 1758 (40.9)
any wheeze 340 (19.5) 438 (17.1) 778 (18.1)
shortnes of breath past 12 months 226 (13.0) 411 (16.1) 637 (14.8)
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4.2.1.2. Spirometry in Helsinki (Studies III-IV)
Altogether 643 acceptable baseline lung function measurements were performed 
during the FinEsS II clinical studies (Kainu 2008). In the BHR sub-cohort, which 
included 292 subjects, all except one had a valid baseline ventilatory function 
determined. 
subjects underwent flow-volume spirometry with a vmax20c spirometer 
(sensorMedics corporation, Yorba Linda, ca, Usa). the ats 1994 standard was 
used for quality criteria for acceptable spirograms. Repeatability criteria followed 
the ERS1993 guidelines (Quanjer et al. 1993); the two largest FVC and FEV1 were 
within 100 ml and 5%, and the two largest PEF within 10%. The calibration of the 
spirometer was performed with a 3-liter pump (syringe, Sensor Medics®, Sensor 
Medics Corporation) at least once a day. A nose clip was used, and a maximum of 
eight maneuvers were recorded. 
The best three spirometric curves were chosen for analysis before and after the 
bronchodilation tests. the best curve was defined as the curve with the largest sum 
of FEV1 and FVC values. The largest FVC and FEV1, and the flow parameters from 
the best curve were recorded for the analyses. A trained technician performed all 
the spirometric measurements, and a physician interpreted the result for the study 
subject. Reference values of Viljanen et al. (1982) and European Community for 
Steel and Coal (ECSC, Quanjer et al. 1993) were used. The results were later re-
computerized from the hard disk of the Vmax20c Sensor Medics. 
4.2.1.3. BHR testing in Kemi (Study I)
Bronchial challenge tests were performed in 382 FinEsS-Kemi subjects, of whom 
bronchial challenge tests with histamine and methacholine were administered to 
86 subjects that were selected using a random procedure. Seven subjects were 
excluded from the analyses since their baseline FEV1 differed ≥ 10% on the bHr 
testing days. Finally, 79 subjects had valid bronchial provocation measured with 
both methods and were thus included in Study I. 
The 79 subjects were tested for BHR with two different bronchial provocation 
methods (Nieminen 1992, Sovijärvi et al. 1993). Of them, 38 started with the 
histamine test and 41 with the methacholine test. In the latter group the mean 
interval between BHR tests was 7.8 (range 6-18) days, and in the former group 
7.2 (range 6-10) days. The tests were performed between 8:20 AM and 3:30 PM. 
before the challenge tests, a flow-volume spirometry with a vmax22 spirometer 
(sensorMedics corporation, Yorba Linda, ca, Usa) was performed according to 
the criteria of ATS (1994). A nose clip was used. Inclusion criteria for BHR tests 
were as follows: a pre-test value of FEV1 over 70% of predicted or over 2.0 L or 
the FEV1/FVC ratio over 78% of predicted (Viljanen et al., 1982), no respiratory 
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table 7. The methacholine (Nieminen 1992) and histamine (Sovijärvi et al. 1993) challenge protocols.
Methacholine
phase concentration (mg(ml) no. inhalations cumulative dose (μg)
1 2,5 1 18
2 2,5 3 72
3 2,5 11 270
4 25 3 810
5 25 10 2600
histamine
phase concentration (mg(ml) no. inhalations non-cumulative dose (μg)
1 4 1 25
2 16 1 100
3 16 4 400
4 16 16 1600
infection within 4 weeks prior to the tests, no severe heart diseases (myocardial 
infarction within 3 months, unstable coronary disease, dysfunction, arrhythmia) 
and no stroke. Subjects using asthma medication were excluded. 
The methacholine test followed the protocol by Nieminen (1992). An inhalation-
synchronized, dosimetric jet nebulizer (Spira Elektro 2, Respiratory Care Centre, 
Hämeenlinna, Finland) was used. Subjects breathed with a tidal volume of 0.5 ± 0.1 
L, and the peak inspiratory flow was 0.5 L/s during the administration of aerosols. 
the nebulization of saline was followed by five increasing doses of methacholine 
chloride at 5-min intervals (0.018 mg; 0.072 mg; 0.270 mg; 0.810 mg; 2.600 mg as 
cumulative doses). (Table 7) FEV1 was measured with the flow-volume spirometer. 
The end-point of the test was a decline of FEV1 by 20% or more from the post-saline 
value or a completed protocol. 
The histamine test was performed according to the method by Sovijärvi et al. 
(1993). A similar nebulizer was used as in the methacholine test. Subjects inhaled 
buffered histamine diphosphate aerosol according to the protocol with four doses 
(0.025 mg; 0.1 mg; 0.4 mg; 1.6 mg) at 5-min intervals (Table 7). FEV1 was measured 
with the flow-volume spirometer. the end-point of the test was a decline of fev1 
by 20% or more or a completed protocol.
During both challenge tests, all symptoms were recorded and lung sounds were 
listened to with a stethoscope. after the provocation, 400 μg of salbutamol aerosol 
was given via a spacer (Volumatic®, Glaxo Wellcome Production, Evreux, France). 
Post-bronchodilatation FEV1 was measured after 10 min. The provocative doses 
inducing a decline of FEV1 of 15% and 20% (PD15FEV1; PD20FEV1 values) were 
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calculated for methacholine and histamine tests by interpolation (Cockcroft et al. 
1983b). The duration of each challenge test was about 30 min.
The majority of the subjects did not achieve a 15% or 20% decline in FEV1 at 
the highest dose of histamine or methacholine, respectively. Their PD values were 
considered censored, as it was only known that their PD was higher than the highest 
dose administered. The censored PD values were extrapolated using the one-point 
and two-point estimation methods (Cockcroft et al. 1977 & 1983b, Jokic et al. 1998) 
if the decline in FEV1 was between 10% and 15% for histamine or between 13% and 
20% for methacholine after the highest dose. for the final analysis, the one-point 
estimation method was chosen. The number of extrapolated PD values was 11 for 
the histamine test and 7 for the methacholine test. Regression analysis was applied 
to describe the possible linear association between the provocative doses (mg) of 
histamine (PD15FEV1) and methacholine (PD20 FEV1), including also extrapolated 
PD values when appropriate. 
the classification of bHr severity used in this study, in terms of pD15FEV1, is 
based on an earlier clinical validation of the histamine challenge test (Sovijärvi et al. 
1993): severe ≤ 0.100 mg, moderate 0.101-0.400 mg, mild 0.401-1.600 mg, and no 
bHr ≥ 1.601 mg. for the methacholine challenge, the limits were adapted from the 
distribution of PD20FEV1 methacholine in a population with asthmatic symptoms 
(Nieminen 1992, Hedman et al. 1998). In terms of PD20FEV1, the classes used were 
as follows: severe ≤ 0.150 mg, moderate 0.151-0.600 mg, mild 0.601-2.600 mg, and 
no bHr ≥ 2.601 mg. the dose response rate (Drr) to methacholine and histamine 
was calculated according to the formula: DRR = last FEV1 decline (%) / last dose 
administered (Peat et al. 1994). 
4.2.1.4. BHR testing in Helsinki (Studies III-IV)
The BHR challenge test was carried out within 14 days from the clinical visit of 
the structured interview, spirometry, and skin prick tests (SPTs). The structured 
interview was done by a physician. A specially trained nurse performed the 
spirometry with the bronchodilatation test, and the SPTs (Pallasaho 2006), and 
the BHR challenge test with histamine.
before the bronchial challenge tests a flow-volume spirometry with a vmax22 
Spirometer (SensoerMedics, USA) was performed according to the criteria of ATS 
(1994). A nose clip was used. The inclusion criteria for the BHR tests were: a pre-
test value of FEV1 over 60% of predicted (Viljanen et al. 1982) or over 1.5 L, no 
respiratory infection within four weeks prior to the tests, no marked heart diseases 
(myocardial infarction within 3 months, unstable coronary disease, dysfunction, 
arrhythmia), and no stroke. Subjects using asthma medication were not excluded. 
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The bronchial challenge was conducted with histamine by using a dosimetric 
tidal breathing method (Sovijärvi et al. 1993) in the same way as in Kemi. The end 
point of the BHR test was at least a 15% fall in FEV1 or the used maximum non-
cumulative dose of histamine 1.6 mg (Table 7). 
4.2.2.5. Fractional exhaled nitric oxide (FENO) measurement in Helsinki  
(Study IV)
according to the finess-ii protocol fenO measurements were assigned for the same 
subjects as the bHr tests. Of the 600 randomly selected subjects, 310 participated 
of whom 295 presented technically acceptable fenO results. earlier assessed 
by Rouhos (2010), the Helsinki cohort consisted of 73 healthy asymptomatic, 
nonsmoking subjects, in whom median and range of fenO was 14.0 ppb (2.1-49.8) 
(Rouhos et al. 2008). for the present study, 277 valid fenO measurements were 
obtained. The ATS (2011), Finnish (Rouhos et al. 2008) and Swedish guidelines 
(Olin et al. 2006) were used in assessment of clinically significant cut off levels, 
fenO ≥ 25 ppb, ≥ 30 ppb, ≥ 45 ppb, respectively. 
All anthropometric data and values of the baseline ventilatory function for studies 
I, III and IV are presented in Tables 6a and 6b.
4.2.2. skin prick tests in helsinki (stuDies iii-iv)
Skin prick tests (SPTs) were performed using the method recommended by a 
European Academy of Allergy and Clinical Immunology (EAACI) position paper 
(Johansson et al. 2001), except as single tests on one forearm. SPTs were done 
in the subjects who were younger than 61 years with 15 allergen extracts (cat, 
dog, cow, horse, birch, timothy, mugworth, Alternaria alternata, Cladosporium 
herbarum, Dermatophagoides pteronyssinus, Dermatophagoides farinae, Acarus 
siro, Lephidoglyphus destructor, Cockroach, Latex) and 2 controls (positive control: 
histamine dihydrochloride 10 mg/ml; negative control: glyserin solvent).
Altogether 498 SPTs were performed in the clinical studies of FinEsS II in 
Helsinki (Pallasaho 2006). Among the 292 subjects who participated in the BHR 
studies, 271 SPSs were performed, whereas 251 valid SPTs were documented. The 
reason for excluded tests (7.4%) was a false positive reaction for the negative control 
solvent in 18 subjects (5 men, and 13 women) and a false negative for the positive 
control (histamine) in 2 subjects. in 239 subjects, valid spts, bHr, and fenO 
measurements were successfully completed. 
57
4 Material and methods
4.2.3. pOstal questiOnnaire (stuDies i-ii)
For both the original general population study cohorts in Lapland and Helsinki the 
same self-administered postal questionnaire was used. It was originally developed 
for the first swedish OLin survey (Lundbäck et al. 1991) in 1985 mainly from a 
revised version (Mikaelsson et al. 1982) of the British Medical Research council 
questionnaire (Medical Research Council’s committee 1960), and further validated in 
the swedish OLin studies (Lundbäck et al. 2001, Lundbäck 1993). This postal survey 
has been used in the FinEsS studies in Sweden (Norrbotten, Örebro, Stockholm, and 
recently in Gothenburg), Estonia (Tallinn, Narva and Saarenmaa), and in Finland 
(Lapland and Helsinki) (Pallasaho et al. 2005).
For study II, which was a follow-up study performed in 2007 (FinEsS-Helsinki 
study of incidence), a self-administered postal questionnaire (Pallasaho et al. 
1999) with two reminders was sent. the postal survey consisted of the same first 
16 questions as the original postal questionnaire from 1996 with a few minor changes 
and, in addition, included six further questions due to local interests of the Helsinki 
part of the study. The extra questions were added to the original FinEsS-Finland 
questionnaire and were concerning smoking, health status, and living conditions 
during childhood. Further, questions related to cold climate, including working 
out-doors and exercise, were excluded.
Definitions
Ever asthma refers to the question ”Have you ever had asthma?” and physician-
diagnosed asthma to “Have you been diagnosed as having asthma by a doctor?”
Allergic rhinoconjunctivitis refers to “Have you had allergic eye or nose symptoms (hay 
fever)?”
Asthma medication: “Do you currently use asthma medicines (permanently or as 
needed)?”
Any wheeze: “Have you had wheezing or whistling in the chest at any time in the last 
12 months?”
Recurrent wheeze: “Do you usually have wheezing or whistling in your chest when 
breathing?”
Longstanding cough: “Have you had longstanding cough during recent years?”
Shortness of breath: “Have you had asthma symptoms (intermittent breathlessness) 
or attacks of breathlessness?” with a further question about having had these 
symptoms during the previous year.
Current smoking refers to those currently or within one year having been smoking 
cigarettes, pipe or cigars.
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Ex-smokers are those who quit smoking at least one year previously.
Quitters smoked in 1996, but were ex- or non-smokers in 2007.
Starters were ex- or non-smokers in 1996, but smokers in 2007.
Countryside/farm living refers to those who lived in the countryside/on a farm during 
the first 5 years of life.
Family history of asthma refers to those, whose parents, sisters or brothers have 
asthma.
Family history of allergic rhinoconjunctivitis refers to those, whose parents, sisters or 
brothers have allergic rhinoconjunctivitis.
Crude cumulative incidence of asthma was calculated by excluding from the population 
at risk those with either physician-diagnosed asthma or ever asthma in 1996, and 
calculating the proportion of new cases of physician-diagnosed asthma in 2007.
Cumulative incidence of allergic rhinoconjunctivitis was calculated by excluding from 
the population at risk those with the condition in 1996, and calculating new cases in 
2007.
Remission of asthma refers to those with physician-diagnosed asthma and either use of 
asthma medication or symptoms of shortness of breath during the previous year or 
recurrent wheeze in 1996, but without these symptoms and medication in 2007. 
Remission of allergic rhinoconjunctivitis refers to those who reported allergic 
rhinoconjunctivitis in 1996, but no longer in 2007.
4.2.4. clinical interview (stuDies iii-iv)
The clinical interview consisted of 162 questions about respiratory symptoms, family 
history of asthma and allergy, living conditions, occupation, smoking habits and 
exposure of environmental tobacco smoke. The complete interview form is presented 
in Finnish and in Swedish in Appendix III and IV. The questions have been referred 
in English in the thesis of Kainu (2008). 
4.2.5. statistical methODs 
4.2.5.1. Statistical methods in Kemi (Study I)
the conventional crossover analysis, anOva for repeated measures, was used 
to compare the continuous variables of baseline FEV1 between challenges. The 
McNemar test was applied to compare the dichotomous variables between histamine 
and methacholine tests. The Chi-square test was used to assess the effect of 
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demographic categorical variables on the BHR and agreement between challenges. 
DRR in histamine and methacholine tests was compared using the method of Altman 
and Bland (1983), and limits of agreement were calculated (Bland & Altman 1986) 
to indicate the level of agreement. Weighted kappa was applied in calculating the 
agreement of BHR severity between the two challenge methods (Liebetrau 1983). 
agreement (%) and kappa coefficients were also assessed using different histamine 
and methacholine cut-off points with non-censored PD values. SPSS (version 12.0 
for Windows, Chicago, USA) and StatXact 6 (Cytel Software Corp., MA, USA, 2003) 
were used for statistical analysis. 
4.2.5.1. Statistical methods in Helsinki (Studies II-IV)
Age group, gender, and family history of allergic rhinoconjunctivitis served as 
covariates in calculation of risk factors for incident allergic rhinoconjunctivitis. 
Multiple logistic regression analysis was used because there was no information of 
time of events. The incidence rate was assumed to be linear and was calculated using 
the formula: a/(11x(b-(a/2))) where a is the incident cases and b the subjects at risk in 
1996. Adjusted cumulative incidence of asthma was calculated after excluding from 
the population at risk besides those with asthma, also subjects on asthma medication 
and those who reported physician-diagnosed chronic bronchitis or cOpD in 1996. 
Further adjustment also excluded those reporting recurrent wheeze or shortness of 
breath during the previous year at baseline in 1996. Crude and adjusted incident rate 
ratios (irr) by gender were calculated, and a p-value <0.05 and a 95% confidence 
interval were considered significant. 
BHR severity, risk factors, and symptoms associated to BHR were determined 
at two different cut off levels of PD15FEV1. Risk factors for BHR were calculated by 
multiple logistic regression analysis including age, gender, family history of asthma. 
and determinants that were significant in the univariate analysis as independent 
variables. the results are expressed as odds ratios (Or) with 95% confidence intervals 
(CI). Chi-square test and Fisher’s exact tests were used to assess differences between 
groups. p-value < 0.05 was considered statistically significant.
The programmes of Statistical Package for Social Sciences (SPSS version 15.0 
for Windows, Chicago, IL, USA) and StatXact 8_2007(Cytel Inc., Cambridge, MA, 
USA) were used for the statistical analysis. 
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5.1. cOmparisOn Of the histamine anD methachOline 
methODs (stuDy i)
Seventy-nine randomly selected subjects (21-73 years), without a diagnosis of asthma 
or chronic bronchitis, were examined. Fourteen percent of the subjects showed BHR 
(histamine PD15FEV1 ≤1.6 mg and methacholine pD20FEV1 ≤2.6 mg) with both of 
the methods, methacholine and histamine. Agreement between methacholine and 
histamine test results at different cut-off levels, defined as non-censored pD values, 
is presented in Table 8. The results of abnormal BHR agreed in 80% of cases (kappa 
=0.45; 95% CI 0.23-0.67), indicating moderate agreement. The agreement was good 
(96%, kappa 0.65), however, for moderate/ severe BHR (BHRms). 
Good agreement was observed between the tests (weighted kappa 0.64; 95% CI 
0.46-0.82) in assesment of bHr severity. classification of bHr severity according 
to PD values in the methacholine and histamine tests is presented earlier on page 
51. BHRms was found in 6.3% of subjects (n=5) with the histamine challenge and 
in 5.1% (n=4) with the methacholine challenge, while mild BHR appeared in 21.5% 
(n=17) and 15.2% (n=12), respectively.
A linear association between histamine PD15FEV1 and methacholine PD20FEV1 
was estimated, including extrapolated PD values in the analysis. The regression 
line was PD20 = 1.088 + 0.967 x PD15 (R2=0.17, n=19). no significant difference 
was present in DRR values obtained from the histamine (mean -8.40 [%/mg]) and 
methacholine (mean -7.97 [%/mg]) challenges (p=0.751).
In subjects with normal spirometry (FEV1, FEV1/FVC, PEF, MEF50) at baseline, 
the agreement of positive BHR in the histamine and methacholine challenges was 
86%. Decreased baseline fev1 (<80% of predicted) did not significantly affect the 
agreement (81% vs. 67%, p=0.407). Neither smoking history (p=0.468) nor body 
mass index (bMi) had any significant impact (p=0.455). 
We found better agreement between PD15 histamine (< 1.6 mg) and PD15 
methacholine (< 2.6 mg) than with PD15 histamine (< 1.6 mg) and PD20 methacholine 
(< 2.6 mg), the kappa values being 0.64 and 0.45, respectively (Table 8). 
The histamine test induced some respiratory symptoms, such as loss of voice, 
throat irritation, cough, and dyspnoea in 63% of subjects (n=50). During the 
methacholine test, the incidence of symptoms was slightly lower; 47% of subjects 
(n=37) reported one or more respiratory symptoms (p=0.047). No difference was 
present between the tests concerning the appearance of adventitious lung sounds by 
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lung auscultation; 9% of subjects showed either expiratory or inspiratory wheezing 
sounds during both tests. 
5.2. prevalence Of BrOnchial hyperrespOnsiveness 
in finlanD (stuDies i, iii-iv)
5.2.1. prevalance Of Bhr in kemi (stuDy i)
Seventy-nine randomly selected subjects (21-73 years) without a diagnosis of asthma 
or chronic bronchitis were examined. The proportion of subjects with abnormal 
BHR (responders) assessed by the histamine test (PD15fev1 ≤ 1.6 mg) was 28%, 
and by the methacholine test (PD20fev1 ≤ 2.6 mg) was 20%.
5.2.2. the prevalence Of Bhr, respiratOry symptOms, anD DereaseD 
lung functiOn in helsinki (stuDies iii-iv)
In Helsinki, 292 subjects of a random sample of the general adult population were 
examined. The proportion of subjects with BHR measured by the histamine test 
(PD15FEV1 ≤ 1.6 mg) was 21.2% (n=62). bHrms (PD15FEV1 ≤ 0.4 mg) was found in 
6.2% (n=18). 
Of the studied subjects, 11% had fev1 below the lower limit of normal (LLN)
(<80% of predicted), 13% had the ratio of FEV1/fvc below LLn (≤ 88% of predicted) 
(Viljanen et al. 1982). fenO was 20.5 ppb±13.8 (mean ± se) in men, and 16.4± 13.0 
ppb in women. Of those studied, 19% (n=52) presented fenO ≥ 25 ppb, whereas 
table 8. Agreement between histamine and methacholine challenges using different non-censored PD 
(provocative dose) cut-off points.
histamine
(PD15FEV1)
Methacholine agreement % kappa (95% ci)
≤ 0.4 mg PD20FEV1 ≤ 0.6 mg 96  0.65 (0.28-1.02)
≤ 1.0 mg PD15FEV1 ≤ 1.3 mg 87 0.61 (0.39-0.83)
≤ 1.0 mg PD15FEV1 ≤ 1.4 mg 86 0.58 (0.36-0.80)
≤ 1.0 mg PD15FEV1 ≤ 1.7 mg 85 0.55 (0.33-0.78)
≤ 1.0 mg PD20FEV1 ≤ 1.3 mg 87 0.61 (0.39-0.83)
≤ 1.0 mg PD20FEV1 ≤ 1.4mg 82 0.37 (0.11-0.62)
≤ 1.0 mg PD20FEV1 ≤ 1.7 mg 86 0.54 (0.30-0.78)
≤ 1.6 mg PD15FEV1 ≤ 2.6 mg 86 0.64 (0.44-0.83)
≤ 1.6 mg PD20FEV1 ≤ 2.6 mg 80 0.45 (0.23-0.68)
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5.8% (n=16) had fenO ≥45 ppb, of whom 38% (n=6) had bHr. prevalence of 
respiratory symptoms and diseases is included in Table 9. 
BHR demonstrated no association with age, gender, BMI, and family history of 
asthma. The prevalence of mild BHR was higher among women than men (18.9% vs. 
7.1%; p=0.010), however, and BHRms associated significantly with aging (p=0.028). 
The mean age of subjects having BHRms was higher compared to subjects having 
histamine PD15FEV1 > 0.4 mg (51.5 vs. 45.8 years, p=0.049). The prevalence of 
individuals with asymptomatic BHR was 2.7%. Among those who had BHR, 12.3% 
were asymptomatic. 
The distribution of BHR severity in subjects without physician-diagnosed asthma 
or chronic bronchitis in the general population was similar in Kemi and in Helsinki 
(Figure 3, p=0.241). In addition, in a sub-analysis, the proportion of BHR, or BHRms 
only, did not show a significant difference between the subjects in kemi and in 
Helsinki, p=0.158 and p=0.961, respectively.
bHr defined as pD15fev1 ≤ 1.6 mg among those who reported shortness of breath 
(sOb) and wheezing during the past 12 months or reported sOb and nocturnal 
asthma symptoms/wheezing was found in 76.5%. reported sOb or wheezing due 
to any food (61.5%), wheezing with breathlessness without having a cold (triad 
52%), use of asthma medication during past 12 months (50%), were more common 
among those with BHR than in the rest of the study cohort (p=0.001, p<0.001 and 
p=0.002, respectively).
table 9. Allergic sensitization, respiratory symptoms, and asthma, n=292. 
Men Women total 
n=123 n=169 n=292
1 positive SPT* reaction, n (%) 55 (50.0) 63 (44.7) 118 (47.0)
≥ 6 positive SPT* reactions, n (%) 10 (9.1) 5 (3.5) 15 (6.0)
Allergic rhinoconjunctivitis (ARC), n (%) 40 (32.5) 71 (42.0) 111 (38.0)
Family history of asthma, n (%) 17 (13.8 ) 36 (21.3) 53 (18.2)
Physician-diagnosed asthma, n (%) 7 (5.7) 6 (3.6) 13 (4.5)
Asthma medication ever, n (%) 21 (17.1) 31 (18.3) 52 (17.8)
Asthma medication past 12 months, n (%) 9 (7.3) 13 (7.7) 22 (7.5)
Inhaled corticosteroids§ 3 (2.4%) 6 (3.6%) 9 (3.1%)
Figures indicate numbers of subjects and their percentage in the groups.
*SPT: skin prick test were performed for men (n=110) and women (n=141) < 61 years (n=251). 
§daily use of inhaled corticosteroids ≥ 200 μg
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Figure 3. Prevalence of different levels of BHR among subjects with no physician diagnosed asthma or 
chronic bronchitis in the general adult population of FinEsS-Kemi and FinEsS-Helsinki cohorts.
Among those with BHRms, 83.3% (n=15) were smokers or ex-smokers, 77.8% 
(n=14) had been exposed to environmental tobacco smoke both at home and at 
work, 55.6% (n=10) had baseline FEV1 below the normal range (Viljanen et al. 1982).
sensitization to at least 6 allergens was significantly associated with bHrms 
(p=0.018). Impaired lung function (FEV1 < 80% of predicted), ever wheeze, nocturnal 
asthma symptoms, sOb, and wheezing during the past 12 months increased the risk 
for BHRms remarkably, as presented in Table 10. Three of the subjects (16.7%) had 
physician-diagnosed asthma (versus PD15FEV1 >1.6 mg 8.1%, p=0.284). Compared 
to the original study population there was no significant difference in the proportions 
of subjects having BMI > 30 (16.7% versus 16.4%) or of subjects being sensitized 
for at least one tested allergen (46.2% versus 47.0%, p=0.438). The age group of 
47-56 years (n=87, 30% of the studied) presented a diminished risk for BHRms 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3. Determinants anD risk factOrs fOr Bhr 
age, gender, family history of asthma and all the determinants that were significant 
in the univariate analysis were included in the multiple regression analysis. Risks 
expressed as odds ratios for PD15FEV1 ≤ 1.6 mg and pD15FEV1 ≤ 0.4 mg based on 
univariate analyses are presented in Table 10. Results of the multivariate analyses 
are presented in Table 11.
5.3.1. Baseline lung functiOn values Of preDicteD 
Baseline FEV1 < 80% of predicted, together with the obstruction (FEV1/ FVC <88% 
of predicted), yielded an increased risk for bHr (Or 7.16). in case the obstruction 
was defined as fev1/ FVC <0.7, the Or was 5.73. baseline fev1 < 80% of predicted 
alone associated with bHr (Or 5.39) and bHrms (Or 14.26). 
In the univariate analysis of lung function variables, MEF50 below lower limit of 
normal (LLN) appeared to be the strongest determinant for BHR and BHRms, and 
this was especially true when combined that with FEV1 < 80% of predicted. When 
MEF50 < LLN was the only single sign of decreased ventilatory function among all 
those studied, it was significantly associated with bHr, Or 2.65 (95% ci 1.21-5.82). 
Among smokers, the risk for BHR was more dependent on FEV1 and on decreased 
FEV1/ FVC, than MEF50 value, as referred to the Study IV, Table 3.
5.3.2. expOsure tO tOBaccO smOke
5.3.2.1. Smoking
Of the subjects, 54.8% (n=160) had smoked at least for a year, from whom bHr 
was determined in 24.4% and BHRms in 9.4% (figure 4). Of the current smokers 
76.6% had tried to quit smoking. 
Smoking increased the risk for BHR as presented in Figure 5. Half a package of 
cigarettes (5-14) daily yielded an Or by 3.11 (95%ci 1.51-6.42) for bHr. Smoking 
habits were associated with BHR severity: smoking more than 25 cigarettes daily 
was a clear risk factor for BHRms (Or 5.05, 95%ci 1.39-18.35). starting to smoke 
at age 13-18 years increased the risk for BHRms by 4.02 (95%CI 1.08-15.02). 
In the multivariate analysis, smoking remained an independent risk factor 
for BHR and BHRms even after adjustment of impaired lung function and other 


















































Figure 4.  Proportion of smokers, ex-smokers and non-smokers in three categories of BHR (marked or 
severe, mild and no BHR) in the general adult population of Helsinki (n=292).  
P-value refers to the trend of smoking habits by the BHR severity classification. 
Figure 5. Association of pack years of smoking and the severity of BHR. 
P-value refers to the trend of increasing number of pack years by the BHR severity.
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table 12. Multivariate analyse of the association of BHR with smoking and lung function data.
pd15Fev1 ≤ 1.6 mg
OR (95%CI)
pd15Fev1 ≤ 0.4 mg
OR (95%CI)
Model 1.
lung function FEV1< 80 % of pred 5.03 (2.36-10.75) 11.35 (3.75-34.36)
Women 1.88 (0.98-3.59) 0.90 (0.30-2.68)
Wheezing or asthma in childhood 3.64 (1.24-10.73) 1.65 (0.18-14.82)
smoking in pack years
non smokers 1 1
< 8.5 pack years 0.68 (0.27-1.72) 0.48 (0.05-4.98)
≥ 8.5 pack years 2.63 (1.33-5.18) 5.03 (1.31-19.31)
Model 2.
obstruction FEV1/ FVC < 0.7 3.99 (1.59-10.01) 12.36 (3.91-39.13)
Women 2.20 (1.16-4.16) 1.35 (0.46-4.01)
Wheezing or asthma in childhood 3.17 (1.08-9.31) 1.32 (0.15-11.54)
smoking in pack years
non smokers 1 1
< 8.5 pack years 0.75 (0.30-1.85) 0.57 (0.06-5.88)
≥ 8.5 pack years 2.68 (1.38-5.23) 5.25 (1.36-20.24)
table 11. Risk in odds ratios (OR) with 95% confidence intervals (CI) for BHR( PD15FEV1 ≤ 1.6 mg) and 
BHRms ( PD15FEV1 ≤ 0.4 mg ); the multivariate analyse, all subjects (n=292) .
pd15Fev1 ≤ 1.6 
mg
ETS at work 
included
pd15Fev1 ≤ 0.4 
mg
ETS at work 
included
or (95%ci) or (95%ci)
age > 47 years 0.70 (0.36-1.38) 0.69 (0.35.1.35) 0.63 (0.17-2.36) 0.57 (0.15-2.16)
Men 1 1 1 1
Women 2.14 (1.08-4.24) 2.09 (1.05-4.16) 1.05 (0.31-3.53) 1.09 (0.32-3.68)
lung function FEV1< 80 % of pred 4.58 (2.07-10.12) 4.67 (2.11-10.34) 10.75 (3.20-36.11) 11.26 (3.28-38.70)
Family history of asthma 1.64 (0.75-3.62) 1.63 (0.74-3.58) 1.42 (0.34-5.97) 1.55 (0.36-6.60)
allergy (atopy or symptoms of arc) 0.63 (0.33-1.21) 0.64 (0.34-1.22) 0.48 (0.15-1.60) 0.48 (0.15-1.60)
Wheezing or asthma in childhood 3.66 (1.22-11.05) 3.63 (1.20-10.95) 2.18 (0.23-21.11) 2.17 (0.22-21.09)
smoking in pack years
non smokers 1 1 1 1
<15 years 0.92 (0.41-2.07) 0.89 (0.39-2.00) 1.51 (0.22-10.23) 1.45 (0.21-9.89)
>15 years 3.87 (1.77-8.43) 3.60 (1.62-8.01) 9.91 (1.83-53.53) 8.28 (1.49-46.00)
ets at work 2.02 (1.00-4.10) 2.11 (0.48-9.36)
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5.3.2.2. Exposure to environmental tobacco smoke
Of the interviewed subjects 41.1% replied that they had never been exposed to ets 
at home, 49.7% had been exposed earlier, and 9.2% were currently exposed to ETS. 
At work, 46.2% had never been exposed to ETS, 45.5% had earlier been exposed, 
and 8.2% currently. Either exposed at home or at work or both comprised in 73.6%. 
Women had more frequently been exposed to ETS at home than men (p=0.012). 
ETS at home or at work was a risk factor for BHRms; Or 3.73 (95%ci 1.05-13.17) 
and 4.65 (95%CI 1.32-16.42), respectively. An additive risk was found for ETS, both 
at home and at work, which yielded a 6.09 fold risk for BHRms (95%CI 1.95-19.01). 
the risk was even higher among smokers (Or 7.31, 95%ci 2.72-19.65). non-smokers 
were not at risk for BHR, however, regardless of the ETS at home or at work, and a 
negative smoking history combined with a negative ETS at home and at work did 
not significantly decrease the risk for bHr (Or 0.75, 95% ci 0.33-1.70). 
5.3.3. allergic cOnstitutiOn
5.3.3.1. Atopy and multisensitization
The prevalence of at least one positive SPT was 49% in the studied cohort from the 
general adult population in Helsinki, and 47% of subjects with BHR were sensitized. 
The prevalence of positive SPT reactions is presented in Table 13. 
allergic sensitization did not significantly correlate with bHr, nor did any 
positive reaction to tested single allergens alone (Table 14). Multisensitization (SPT 
response to ≥ 6 allergens) was significantly associated with bHrms (p= 0.018), with 
elevated fenO (> 25 ppb) (p=0.045) and symptoms of allergic rhinoconjunctivitis 
(arc) (p=0.003) (figure 6). the reported symptoms of food allergy yielded an Or 
of 6.67 risk for BHR (95%CI 2.10-21.19), which was not associated with BHRms. 
5.3.3.2. Atopy and airway obstruction
Atopy combined with obstruction (FEV1/ FVC< 88% of predicted) yielded an 
increased risk for bHr (Or 6.32). in the multivariate analysis, multisensitization 
and obstruction remained as independent risk factors for BHRms, Or 4.68 (95%ci 
1.10-21.65) and Or 8.29 (95%ci 2.47-27.81), respectively. 
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table 13. Prevalence (%) of positive SPT reactions.
Men (n=110) Women (n=141) total (n=251)
% % %
Dog 22.7 17.7 19.9
Cat 22.7 15.6 18.7
Birch 16.4 21.3 19.1
Timothy 23.6 14.2 18.3
Mugworth 11.8 12.1 12.0
HDM1 6.4 2.1 4.0
HDM2 8.2 4.3 6.0
Any pollen 35.5 29.8 32.3
Any animal 31.8 23.4 27.1
Any allergen 50.0 44.7 47.0
HDM1. House dust mite1, Dermatophagoides pteronussinus
HDM2. House dust mite2, Dermatophagoides farinae
No significant difference in the prevalence by gender.





0.4 mg (BHRms) and ≤ 1.6 mg (BHR).
pd15Fev1 ≤ 0.4 mg pd15Fev1 ≤ 1.6 mg
OR 95% CI OR 95% CI
atopy
SPT any positive 0.8 (0.3-2.1) 1.0 (0.5-1.8)
SPT ≥ 4 positive 1.7 (0.4-6.2) 1.2 (0.5-2.9)
SPT ≥ 6 positive 4.7 (1.2-18.8) 1.4 (0.4-4.7)
SPT cat positive 2.7 (0.8-9.1) 1.1 (0.4-2.7)
SPT birch positive 0.6 (0.1-2.9) 1.0 (0.5-2.2)
5.3.4. timing Of the Bhr tests
The histamine challenge test was carried out during the birch pollen season (April-
June) for 28% (n=83) of those studied. These subjects did not differ in terms of the 
prevalence of symptoms of ARC. However, those subjects tested in April to June 
presented an increased risk for BHRms (Or 2.70, 95% ci 1.03-7.07). 
5.3.5. fractiOnal exhaleD nitric OxiDe (fenO)
Mean fenO in the studied population (n=277) was 18.09 ppb (sD 13.47; 2.13-95.60). 
the association between fenO and bHr was strongly dependent on smoking habits. 
Only in non-smokers with bHr, fenO was >25 ppb, and significantly higher 
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compared to the remaining subjects (p=0.008). This was not true for smokers or 
ex-smokers with BHR (Study IV, Figure 2).
fenO was lower among smokers exposed at home and at work compared to 
the remaining subjects, 13.35 ppb versus 19.06 ppb (p=0.008), in contrast, non 
smokers with no ETS exposure at home nor at work had a higher fenO (22.60 
ppb versus 17.30 ppb, p= 0.020). Current exposure to ETS was associated with a 
lower fenO (13.2 ppb) compared to non-exposed (19.3 ppb) (p=0.002).
subjects who had fenO ≥30 ppb were at more than five-fold risk for bHr 
when exposed to ets at work (Or 5.59; 95%ci 1.86-16.81). fenO cut off levels 
≥ 25 ppb and fenO ≥ 45 ppb yielded increased risk for bHr, Or 2.98 and Or 
5.00, respectively.
5.3.6. respiratOry symptOms
Many of the reported respiratory symptoms associated significantly with bHr (table 
10.) In the group of subjects with BHRms, more significant associations, i.e. higher 
Ors for symptoms, were found (table 10).
Seventeen individuals (5.8%) reported asthma or wheezing in childhood. All of 
them had baseline FEV1 ≥ 80% of predicted, but bHr was found in seven (41%). 
In those individuals with a wheezing history, father’s smoking (65%) was more 



















Figure 6. Prevalence of BHRms, elevated fractional exhaled nitric oxide (FENO >25 ppb) and reported 
symptoms of allergic rhinoconjunctivitis (ARC) in different groups of allergic sensitization in 




the childhood wheezers compared to the remaining of the studied did not differ 
(p=0.379). Mother’s smoking did not associate with BHR.
Longstanding cough did not associate with BHR, but cough in the mornings 
yielded a 2.17 fold risk for BHR, and ever wheezing increased the risk to 2.88 fold 
(95%ci 1.60-5.18). nocturnal asthma symptoms, sOb/wheezing during the past 12 
months, and reported sOb/wheezing induced by air pollution, increased the risk 
for BHRms by 6.83 (95%CI 1.93-24.19), 5.74 (95%CI 1.66-19.88), and 5.16 (95%CI 
1.66-16.01), respectively. 
5.3.7. physician DiagnOseD asthma anD use Of asthma meDicatiOn 
The prevalence of physician diagnosed asthma was 4.5% (n=13), of whom 
69.2% were smokers or ex smokers. FEV1/ FVC< 0.7 was found in 8.6% (n=25) 
of the subjects of whom 2 had an asthma diagnosis. FEV1/ FVC<0.7 after 
table 15. Demographic data of all subjects stratified according to BMI.
all subjects
BMi (kg/ m2) 26 (17-55) <25 25-30 >30
No. of subjects 292 139 105 48
% of subject 100 48 36 16
Age mean (range) 46 (26-66) 44 (27-65) 48 (27-65) 48 (26-66)
Men (%)// Women (%) 42// 58 39// 61 48// 52 40// 60
Fam Hist Asthma (%) 18 20 16 17
Physician dg.asthma (%) 5 4 5 6
lung Function
FEV1 [L] mean (range) 3.37 (1.71-5.90) 3.40 (1.84-5.90) 3.45 (1.88-5.47) 3.10 (1.71-4.55)
FVC [L] mean (range) 4.34 (2.15-8.03) 4.37 (2.68-8.03) 4.47 (2.39-7.46) 3.98 (2.15-6.27)
FEV1 < 80% of pred (%) 13 14 9 19
FEV1/ FVC < 0.7 (%) 7 9 6 2
sMoking
Non smokers (%) 41 48 33 42
Ex smokers (%) 26 18 33 31
Current smokers (%) 33 35 33 27
Bhr_histamine pd15Fev1
≤ 0.400 mg (%) 6 6 7 6
0.401-1.600 mg (%) 15 14 14 19
>1.601 mg (%) 79 80 79 75
Predicted values according to Viljanen et al. (1982).
72
bronchodilattaion test was found in 3.8% (n=11). Eight subjects (2.1%) reported 
their physician diagnosed chronic bronchitis, whereas reported symptoms for 
chronic bronchitis indicated of a prevalence of 7.9% (n=23). Physician diagnosed 
asthma was associated with BHRms (Or 5.28, 95%ci 1.31-21.22), whereas chronic 
bronchitis, neither physician diagnosed nor based on reported symptoms, did 
not significantly associate with bHr. 
Of those subjects with recent use of asthma medication, 27% reported physician 
diagnosed asthma, and a half of them did not show BHR. No subjects with earlier 
asthma medication had severe BHR. Recent use, and ever use of asthma medication 
was associated significantly to bHr, Or 4.29 (1.76-10.45) and Or 2.11 (1.08-4.09), 
respectively. 
5.3.8. OBesity
Sixteen percent of the subjects were obese (BMI > 30 kg/m2), among whom the 
FEV1/fvc ratio was ≥0.70 except in one. table 15 presents the demographic data of 
subjects stratified according to bMi. bMi and bHr did not associate significantly. 
5.4. inciDent asthma in the stuDy pOpulatiOn 1996-
2007 (stuDy ii)
5.4.1. inciDent asthma in 11 years’ fOllOw-up DefineD By pOstal 
surveys
5.4.1.1. Changes in the prevalences 1996-2007 (Study II) 
The prevalence of physician diagnosed asthma, use of asthma medication, and 
reported symptoms of ARC had increased by the 11 years’ follow up, which was 
not true for respiratory symptoms. Regardless of aging in this cohort, shortness of 
breath (13% versus 15%), for example, did not significantly increase.
In 2007, ARC was reported by 41% of subjects, and both physician-diagnosed 
asthma and use of asthma medication by 9%. The greatest increase in prevalence 
was observed in symptoms of ARC, from 38% to 41%, whereas a 3% increase 
existed in the asthma diagnosis and use of medication. Current smoking decreased 
significantly over the follow up time, from 31% to 23%. the greatest decrement of 
13% was seen in the group of young smoking women (31-40 years). The women 
aged 41-80 years presented only a 7% decrement, and the decrement in men was 
even less, 5% on average. 
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5.4.1.2. Incidence of asthma 
In the general population cohort of the FinEsS-Helsinki study (4302 individuals), 
a 4.0% cumulative incidence was found during the 11 years’ follow up from 1996 
to 2007. These 157 individuals with new adult onset asthma corresponded to an 
incident rate of 3.7/ 1000/ year among those 3966 subjects who constituted the 
cohort at risk for asthma in 1996.
When those subjects with asthma medication, physician diagnosed chronic 
bronchitis, or cOpD were excluded from the population at risk in 1996 (n=3821), 
132 new adults onset asthmatics remained, leading to an adjusted incident rate 
of 3.2/ 1000/ year, among men 2.5/ 1000/ year and in women 3.7/ 1000/ year, 
p=0.026. If subjects with recurrent wheeze or shortness of breath were also excluded 
from the cohort at risk, the incidence rate was 2.5 / 1000/ year, 1.7 for men and 
3.1 for women (p=0.008), respectively. 
In 2007, remission of asthma occurred in 43 (17%) of those 254 individuals, 
who reported active asthma in 1996. Of these 43 individuals, 11 men and 32 women 
were free from symptoms and did not use asthma medication. 
5.4.1.3. Incidence of allergic rhinoconjunctivitis (ARC)
New adult onset cases of ARC occurred in 447 individuals, a majority of whom 
were women (274 versus 173), p=0.012. The annual crude incident rate was 16.8/ 
1000 persons. incident arc was greatest in the age group 31-40 years. Of these 
youngest individuals, 23% reported development of ARC over the 11 years’s follow 
up, whereas only 14% of those were in the oldest age group of 71-80 years. Living 
in the countryside or on a farm in early childhood (<5 years) was associated with 
a lower incidence of arc (p=0.022 and p=0.008). smoking was not significantly 
associated with incident ARC. Family history of ARC yielded an increased risk for 
incidence of ARC by 1.73 (95%CI 1.34-2.25). In a multivariate model. ARC was an 
independent risk factor for incident asthma. 
In 2007, remission of ARC was reported by 18% (n=296) of those 1635 individuals 
who reported ARC in 1996. More men were in remission compared to women (21% 
versus 17%, p=0.06). 
5.4.1.4. Determinants of incident asthma 
Aging was associated with an increased risk for incident asthma above the age of 
61 years, leading to a more than two-fold risk in senior citizens (Or 2.33; 95%ci 
1.30-4.18). A similar level for an increased risk was found in association with female 
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gender, family history of asthma, history of allergic rhinoconjuctivitis, and long-
term smoking (Study II, Table 4). When individuals with asthma medication and 
cOpD were excluded from the population at risk, i.e. presenting the adjusted risk, 
the determinants for incident asthma remained. With this adjusted criteria, a status 





6.1. DiscussiOn Of the main results Of stuDies i-iv
6.1.1. methODOlOgy Of measuring Bhr 
In the present studies, BHR was assessed with inhaled histamine diphosphate 
or methacholine by using a nebulization method with controlled tidal breathing 
(Nieminen 1992, Sovijärvi et al. 1993). The methods, which have not been compared 
before, showed good repeatability. Both the histamine and methacholine methods 
have been used, however, in paediatric and adult respiratory research (Helenius 
et al. 2002, Sovijärvi et al. 2003, Kyllönen et al. 2006, Malmström et al. 2008, 
Lindström et al. 2009, Malmberg et al. 2010) and commonly in clinical diagnostics 
in Finland. 
The present histamine test (Sovijärvi et al. 1993) has been evaluated in comparison 
with other direct airway challenge methods by Chinn and Schouten (2005). Its high 
intraclass correlation coefficient (0.95) was the best in the comparison with other 23 
BHR methods reported in this review. The inhalation synchronized tidal breathing 
and the optimal composition of the histamine and methacholine particles (mass 
median diameter 1.6μm, size 75% of the particles 1-3 μm) leads to less non-uniform 
distribution of the constrictor to central and peripherial parts of the airways than 
would larger particles. 
Deposition studies of the metacholine test (Nieminen et al. 1987) demonstrated 
that alveolar deposition in asthmatic subjects was 43% of the output of the nebuliser. 
The deposition of radiolabelled methacholine exhibited a 17% increase in the lung 
deposition in healthy subjects when the nebuliser was operated in an early phase 
of tidal volume, 80ml from the beginning of inspiration, used in the present studies 
versus 320 ml from the beginning of inspiration. inspiratory flow rate was set to 
be slow, 0.5 L/s and tidal volume 0.5 L in order to improve the reproducibility 
of the consecutive measurements (Nieminen et al. 1987), i.e. to avoid changes in 
bronchomotor tone due to the inspiratory manouvere (Lim & Ang 1997, Sinard et 
al. 2005, Cockcroft 2008, Prieto et al. 2008).
In Study I (Kemi, North Finland), the choice of subjects selected for the 
comparison was of clinical interest, which met the aims of the Brussel declaration in 
2004 for high-priority studies in terms of asthma and respiratory diseases (Holgate 
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et al. 2008). The subjects included presented a random sample of individuals, the 
majority of whom were symptomatic, but did not have asthma or chronic bronchitis. 
the results of study i affirmed that the methods were in good agreement in 
staging the severity of BHR (weighted kappa 0.64; CI 95% 0.46-0.82). Baseline 
FEV1 level did not significantly affect the agreement. 
Values of the baseline FEV1 measurements, before both the methacholine and 
histaminen tests, were evaluated prior to the final selection of the cases for the 
further comparative analysis. The results in PD15/20FEV1 are dependent on the 
percentage change from the baseline FEV1. In order to study the agreement of 
these two methods, the baseline FEV1 values did not differ more than 10% between 
the metachcoline and histamine testing days. This obviously resulted in a selection, 
in which those subjects with the greatest intra-individual FEV1 variability were 
excluded from the final study cohort. it is possible that this standardization manner 
excluded some of those subjects who potentially would have presented significant 
BHR. However, it did not affect the agreement between the studied BHR methods. 
The histamine and methacholine test were carried out seven days apart. The 
order of testing did not have a significant association to the results. furthermore, 
the majority of subjects were tested during the morning hours (mean at 11 am), 
however the timing of the bHr measurements did not influence the results of 
agreement. Tachyphylaxis of methacholine has been reported to last over for 4-7 
days (Fujimura et al. 1999, Sinard et al. 2005), however histamine has not been 
shown to accumulate or decrease in response in serial measurements (Sovijärvi et 
al. 1993, Sinard et al. 2005). 
In addition to the original cut off levels for histamine PD15FEV1 and metacholine 
PD20FEV1 (Nieminen 1992, Sovijärvi et al. 1993), different PDFEV1 cut-off levels were 
investigated. The agreement of methacholine and histamine test results was inversely 
related to the PD values; better agreement was found in more pronounced BHR, 
i.e. in subjects with clearly sensitive airways to direct stimuli. Since subjects with 
diagnosed asthma were excluded, the majority of patients did not show abnormally 
increased BHR when using the clinically validated points of abnormality. We found 
better agreement between PD15 histamine (< 1.6 mg) and PD15 methacholine (< 2.6 
mg) than with PD15 histamine (< 1.6 mg) and PD20 methacholine (< 2.6 mg). This 
is in accordance with the results by Malo et al. (1983), they suggested a lower FEV1 
cut of level (-6%) to be used in general population studies of bHr. Our results on 
the lnDrs did not increase the value of our findings gained by the pD15FEV1 method. 
The histamine test induced slightly more respiratory symptoms than the 
metacholine test. This is line with earlier studies (Juniper et al. 1978, James & 
Ryan 1997). Extrathoracic airway obstruction or irritable laryngeal reactivity might 
constitute observed respiratory symptoms (Bucca et al. 1995a&b, Rolla et al. 1997). 
In Study I, expiratory wheezing, as a sign for peripheral obstruction, accounted in 
a similar degree during both provocation tests. In accordance with this, there is 
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evidence from a recent study from Leuven, Netherlands (Janssens et al. 2012) that 
symptom perception during a histamine challenge test could predict upcoming 
problems with asthma treatment.
In Studies I, III, and IV, the number of subjects was relatively small. The 
representativeness of the present cohort for the BHR-Helsinki study (Studies III 
and IV) was compared to the original study cohort of FinEsS I postal survey by 
gender and age, and the replies of the postal survey (Pallasaho et al. 1999). In 
the present study cohort the physician diagnosed chronic bronchitis (question 4) 
and symptoms related to chronic bronchitis (questions 8A and B) were slightly 
less prevalent than in the original study population, but prevalences of reported 
respiratory symptoms, symptoms of allergic rhinoconjunctivitis (ARC), physician 
diagnosed asthma, and smoking were alike.
6.1.2. prevalence Of Bhr 
In the general adult population of Helsinki, the prevalence of BHR was 21%, and 
severe or moderate BHR was found in 6% of the studied subjects, respectively. In 
Kemi the prevalence of BHR and BHRms were of a similar level, although assessed in 
a randomly selected adult cohort of general population without physician diagnosed 
asthma or chronic bronchitis. Both these results agree with the range of BHR found 
in the European Community Respiratory Health Survey (ECRHS), where the 
prevalence of BHR varied from 3-28% in 16 countries, with a median prevalence 
of 13 % (Chinn et al. 1997). Referred by Jansen (1999) the prevalence of 11 BHR 
population studies published in 1984-1994 presented the variation from 6-35%. 
All these percentages of prevalence are in accordance, but show large variation. 
these findings indicate no increase in bHr in the general population during the 
past three decades, which is in line with an observed decline in BHR’s prevalence 
found in the 11 year’s follow up in the SAPALDIA study (Curjuric et al. 2011). The 
diversity of these presented percentages may be explained by the different methods 
and study designs employed. 
cohorts may differ significantly from each other. furthermore, the inclusion 
criteria for the subjects vary, which causes variation in the reported prevalence and 
outcomes. In the Swiss SAPALDIA study, the prevalence of BHR was 13% (Curjuric 
et al. 2011), however the inclusion criteria for the BHR test was different from 
ours, restricting more subjects out of the study cohort by excluding subjects who 
reported use of asthma medication, had a baseline FEV1 <70% or FEV1/ FVC <80% of 
predicted, or had a post saline drop >10% of the maximum baseline FEV1 value. The 
last mentioned was not even measured by our BHR protocols. The Normative Aging 
study (Sparrow et al. 1987 &1991) included only healthy men, thus not representing 
a general population. Regardless of the BHR method in use and the proportion 
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of hyperreactive subjects, the percentages of symptomatic individuals show great 
variation, as listed in Table 3.
The prevalence of asymptomatic subjects with BHR was lower here than reported 
in the previously mentioned SAPALDIA study (12% versus 51%), which indicates 
the usefulness and better sensitivity of the challenge method used here in general 
population studies (Sovijärvi et al. 1993). Reporting the prevalence of asymtomatic 
BHR faces obstacles due to the different criteria presented for an asymptomatic 
subject. As previously described (Rijcken et al. 1987), asymptomatic subjects were 
defined here based on a questionnaire (kainu 2008, p.47-48). 
Histamine and methacholine provocations have been compared from different 
viewpoints with other provocation methods (Anderson et al. 2002, Sterk 2002, Joos 
et al. 2003, Choi et al. 2003, Anderson & Brannan 2003, de Meer et al. 2004). Some 
studies have described indirect methods such as hypertonic saline or mannitol to be 
more specific for asthma (andersson et al. 2002 & 2003), typically in comparison 
to measures of acute eosinophilic inflammation found in asthmatic patients. the 
directly acting bronchoconstrictor agents, however, have been regarded as more 
sensitive in diagnosing asthma than the indirect stimuli (Joos et al. 2003, Koskela 
et al. 2003a&b). In terms of physician diagnosed asthma, the cut off level for BHRms 
used here gave the same prevalence for physician diagnosed asthma as reported by 
the postal survey preceding (Pallasaho et al. 1999). The presented histamine test 
is thus suitable in assessment of BHR in population studies. 
6.1.3. Determinants Of Bhr
6.1.3.1. Decreased FEV1 
The decreased FEV1 was the main determinant for an increased BHR in the present 
studies. Spirometric values were employed for prediction in the regression analysis, 
where the height and weight of the participants were adjusted. 
these results indicate that airway obstruction at baseline, defined as fev1/ 
FVC < 88% of predicted or FEV1/ FVC < 0.7, causes a 4-fold higher risk for BHR, 
and increases to 7-fold when combined with a decreased FEV1 value. The risk of 
decreased ventilatory functions was doubled among the smokers. As a sign for early 
airway closure, the MEF50 below LLN independently associated with an increased 
risk for BHR and BHRms, at the same magnitude as a decreased FEV1 value. Results 
from others, also assessed in a general adult population cohort, report of this close 
relation of decreased FEV1 and increased BHR (Rijcken et al. 1988, Jansen et al. 
1997, de Marco et al. 1998, Schwartz et al. 2002, Scichilone et al. 2005), but no 
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such results by the MEF50 parameter and BHR to histamine in an adult general 
population have been published.
6.1.3.2. Gender
in study iii, gender and the bHr were not associated, similar to the findings reported 
by PausJenssen and Cockcroft in 2003, but contradictory to some other studies 
(Malo et al. 1983, Jögi et al. 2004). 
Gender difference has been observed in studies on prevalence and incidence 
of asthma (Leynaert et al. 1997, Chinn et al. 2006, Leynaert et al. 2012). The 
determinants for this remain unanswered, as for BHR. Curjuric et al. (2011) 
demonstrated that the increase in BHR slope appeared in women 10 years earlier 
in age in comparison to men, but it was not associated with increase in the weight 
in women. Adipose tissues in women (Leynaert et al. 2012), improved diagnostic 
methods, and increase awareness of asthma (Lundbäck et al. 2001) have been under 
discussion as potential contributing factors. The use of fairly old reference values 
for ventilatory parameters (Viljanen et al. 1982, Quanjer et al. 1983) could impact 
on the number of false positive cases of asthma, which has not been discussed in 
detail in the literature. Thus, overall, the gender effect remains to be elucidated. 
6.1.3.3. Respiratory symptoms and BHR
BHR was associated with many respiratory symptoms and irritants in this study, 
which is in accordance with the known nature of BHR in children (Salome et al. 
1987, Pattemore et al. 1990, Malmberg et al. 2008) and in adults (Salome et al. 
1997, Rijcken et al. 1987, Sparrow et al. 1987, Woolcock et al. 1987, Burney et al. 
1994, Xu et al. 1997, Jansen et al. 1999a). The symptoms alone cannot reliably 
explain BHR, as presented  in Table 3. Most of the respiratory symptoms were 
related to mild BHR, and much fewer symptoms seemed to be related to BHRms, 
which probably reflects to the better asthma positive predictive value, especially 
when it concurs with a low cut off value for BHR (Koskela et al. 2003a&b). 
In the present study, long-lasting cough was not associated with BHR in adults, 
as found by de Marco et al. (1998). Cough seems not to be a typical symptom of 
BHR. This differs from the pediatric patients, in whom cough is more frequently 
associated with bHr, and it is the most sensitive finding for wheezing and respiratory 
tract illness in children (Rivera-Spoljaric et al. 2009). 
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6.1.3.4. Smoking 
A dose-dependent pattern of smoking habits was demonstrated in this assessment 
of BHR in the general adult population. This data evidently corresponds to the fact 
that increasing smoking habits associate with marked BHR. ETS at home, and 
especially at work, are risk factors for BHR, in which the smokers had the highest 
risk for bHr. these findings regarding smoking and ets are in agreement with the 
data of earlier studies by Chinn et al. (2005), Schwartz et al. (2002) and Janson 
et al. (2001). 
A third of continuous smokers had started in their teenage years, and a third of 
them had BHR, whilst a tenth presented BHRms. Starting to smoke at early age of 
7-14 years, increased the risk for BHRms significantly (Or5), and starting smoking 
when a teenager (15-19 years) doubled the risk for BHR in adulthood. Studies of 
exposure to tobacco smoke indicate that the time and length of the exposure both 
impact on ventilatory function and BHR (Janson et al. 2001 & 2006, Chinn et 
al. 2005, Chaudhuri et al. 2006), in addition to the acute inflammatory reactions 
triggered on the respiratory epithelium (Barnes 2008 & 2009, Louhelainen et al. 
2010).
Smoking leads to remodelling changes on the airways, similar to those changes 
observed with asthma (Karjalainen et al. 2000, Vignola et al. 2000, Colice 2002, 
Chetta et al. 2003). according to the recent findings by tsurikisawa et al. (2010), 
the presented histamine test could serve well as a measure for changes of airway 
remodelling. Furthermore, they established that BHR to histamine, but not Ach, 
was associated with histopathological changes typical for airway remodelling. They 
examined 50 adult patients with severe asthma, but no smokers. They found that 
ASM thickness was inversely correlated with BHR to histamine but not to Ach, thus 
indicating that their final conclusions could be applied to remodelling changes typical 
for a long duration of smoking as well. Willemse and colleges (2004) have earlier 
shown that a one-year smoking cessation improved both direct and indirect airway 
hyperresponsiveness in cOpD, thus supporting the role of bHr measurements 
also in ever smokers. 
6.1.3.5. Severe respiratory infection, wheezing or asthma in childhood
The results presented here have revealed that respiratory problems in early 
childhood, which cause wheezing, or a post infectious sensitivityof the airways after 
a severe respiratory infection, are associated with BHR in adulthood. 
Other epidemiological studies have also made these arguments (sunyer et al. 
1997, Sears et al. 2003, Vonk et al. 2004, Toelle et al. 2004, Porsbjerg et al. 2006), 
however determinants of causality, a pathway of pathophysiological factors from 
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early childhood to adulthood and aging, have not been fully elucidated (Prescott 
& Nowak-Wegrzyn 2011). 
Viral infections such as RSV and adeno virus have been associated with increased 
risk for BHR and asthma in childhood (Lemanske et al. 2005, Stein et al. 1999, 
Kotaniemi-Syrjänen et al. 2007). The recent immunopathological studies on 
respiratory diseases indicate that the inflammatory th1/ th2 pathways interact 
following a virus infection (strickland and Holt 2011). Young atopic individuals 
exhibit the highest the risk for asthma (Holt et al. 2010). Animal models suggest 
that variation on virus-host interactions exist (Sutton et al. 2007), and some viruses 
are able to cause the final inflammatory response by modulating the actions of high-
affinity ige receptor on lung dendritic cells (grayson et al. 2007). These interactions, 
and modulation of inflammatory responses, could be studied in older individuals, 
among whom BHR is believed to be increased (Scicilone et al. 2005), but skin 
reactivity is less frequent (Cline & Burrows 1989). 
 results of the present study indicate that wheezing below the age of five results 
in an increased risk for at least mild BHR in adulthood, which has to be considered 
in planning and publishing new treatment guidelines for baby wheezers (Panickar 
et al. 2009). There is no available data on longitudinal studies that negate a long-
term effectiveness of anti-inflammatory treatment in childhood asthma or recurrent 
wheeze in terms of current or incident BHR in adulthood (Jartti et al. 2007). 
6.1.3.6. Rhinitis 
In the cross sectional FinEsS-Helsinki (Study III), no symptoms were evident for 
allergic rhinoconjunctivitis (ARC) that has the potential to increase the risk for 
BHR. Allergic rhinoconjuctivitis doubled the risk for incident adult on-set asthma 
(Study II), as reported by other’s (Boulay & Boulet 2003, Shaaban et al. 2008).
Rhinitis and sinusitis are known to be associated with BHR, even in the absence 
of asthma symptoms (Henriksen et al. 2001) or physician diagnosed asthma (Rolla 
et al. 1997). as found by shaaban (2008), rhinitis and bHr have been defined 
independent risk factors for incident asthma. The mutual effects of rhinitis and BHR 
have not fully been established, however. Studies on rhinitis as a risk factor for BHR 
are scarce. In an 8-year follow-up, Shaaban et al. (2007) found 10% cumulative 
incidence of BHR among subjects with allergic rhinitis, 7% for subjects with atopy 
without rhinitis, and 5.5% for subjects negative for both these conditions. Of those 
individuals who had BHR at baseline (7%), 35% of them carried allergic rhinitis. 
Remission of BHR in follow up was increased among those receiveing nasal-steroid 
medication (Or 0.33; 95% ci 0.14-0.75). 
Subjects BHR tested in April to June had an increased risk for BHR in the 
present study, regardless of the atopic constitution or symptoms of ARC. This is in 
82
accordance with results by Madonini et al. (1987), who reported a seasonal increase 
in BHR in rhinitis patients. Subjects with rhinitis and BHR have been reported to 
express distinct in inflammation markers, including ebc, pH, ebc nitrite, and 
fenO, which have been suggested to serve as biomarkers for identifying rhinitis 
patients at risk for developing asthma (Skiepko et al. 2011). 
6.1.3.7. Allergic sensitization 
The decision of the age limit for SPTs only for individuals under 61 years was based 
on earlier data on decreased skin reactivity in later adult life (Cline & Burrows 1989). 
The lack of SPT results in individuals over 61 years led to neglation of some these 
results, thus probably decreased statistical power of some the findings reported 
here. From this point of view, the age of studied subjects has been a limitation in 
the ECRHS studies as well. In those studies, the subjects have been 20-44 years 
at the baseline (1990-1994), and the ECRHS I and II reports do not include data 
of the sensitization and BHR in subjects over 61 years either (Harrop et al. 2007, 
Gunnbjörnsdóttir et al. 2009).
allergic multisensitization was significantly associated here with bHr response 
to histamine, while sensitization to one or a few allergens was not. This is in line 
with the findings by kerkhof et al. 2003, in which only high levels of specific ige for 
indoor allergens, i.e. multisensitization, associated with BHR. This is in accordance 
with a large general population study from the Vlagtwedde and Vlaardingen study 
in Netherlands where the high serum total IgE levels (< 100 kU/L) associated with 
BHR both in symptomatic and asymptomatic individuals (Jansen et al. 1999a). They 
also found that skin test positivity associated with BHR only in symptomatic subjects, 
and these findings agree with results by kerkhof et al. (2000) of the ECRHS study, 
in which low levels of specific ige to indoor allergens associated with symptoms 
only if BHR existed. Results by Patelis and colleges (2012) indicated that the risk 
for asthma increases with multiple sensitisations to different allergen groups. 
In the present cohort, the prevalence of at least one postive SPT reaction was 49%. 
Earlier studies, such as a study with younger male conscripts (Haahtela et al. 1980), 
and another study with university students (Kilpeläinen et al. 2001), indicate great 
variation from 30% to 70% of a single positive SPT reaction. The younger cohorts 
present higher percetages, as do symptomatic, in comparison to asymptomatics 
(Haahtela et al. 1980, Kilpeläinen et al. 2001, Pallasaho et al. 2006). Geographical 
factors may explain some diversity in the reported percentages observed, as has been 
reported of the appearace of a single positive SPT in between two otherwise similar 
cohorts from Karelia, one from the Finnish and the other one from the Russian 
side of border (Vartiainen et al. 2002). In the present cohort, the prevalence of 
non-atopic subjects who reported ARC symptoms constituted in 32% of all those 
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subjects who reported arc, which is regarded as a high percentage. this finding 
should be interesting to confirm and to study further, also in a longitudinal setting.
Recent publications in allergy raise the interest in explaining airway 
hyperresponsiveness by immunological hyporesponsivess (von Hertzen et al. 2009, 
Joenväärä et al. 2009), which then could link the allergen induced symptoms of 
rhinoconjuctivitis and multisenzitation to BHR as found here, and as has been 
reported by others (Spallarossa et al. 2003) among polysensitized teenagers. 
Responses to allergen exposure on nasal respiratory mucosa have been shown 
to activate the cell caveolar transit system in a different fashion for atopic and 
non-atopic subjects, in which the pathology and symptoms are associated to 
hyporeactivation of the intracellular systems involved (Renkonen et al. 2009, Mattila 
et al. 2010). This could explain individual differences in the response to spring 
pollen season, where atopic subjects may also react to different degrees. Boulay & 
Boulet (2002) has suggested that a well functioning adaptation process in allergic 
rhinitis subjects may protect them from developing asthma, which might explaining 
some of these inter-individual differences as well.
6.1.3.8. Fractional exhaled nitric oxide (FENO)
exhaled nitric oxide (fenO) leveled the bHr severity only among the non-smokers, 
but bHr and fenO were not associated in the general adult population in Helsinki. 
among all those studied, the fenO level was highly associated with the allergic 
constitution, defined as number of positive spt reactions and reported symptoms 
of ARC. Similar kinds of results have been reported by Ekroos et al. (2009) and 
Rouhos et al. (2005), who have studied young male non-smoking conscripts with 
mild asthma. 
these findings support the fact that smoking can reduce fenO by different 
mechanisms (Silkoff et al. 2000, Török & Leuppi 2007). Results by Rouhos et al. 
(2010) suggested that smoking attenuates the increase in nOexp in atopic, but not in 
non-atopic young adults with asthma. In our study a different age group was studied. 
6.1.3.9. Obesity
in the studies iii-iv, obesity (bMi>30) was not significantly associated with bHr. 
We found that the proportion of subjects with FEV1 below LLN was the same in the 
three BMI categories. However, the baseline values for FEV1 [L] and FVC [L] were 
significantly lower among the obese (bMi > 30) compared to less obese subjects. 
Of the obese, all except one subjects had the ratio fev1/ FVC >0.7, and none of 
the obese had FEV1 and FEV1/ FVC of predicted below LLN.
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Much speculation exists about the association of asthma and obesity, whether 
an increased risk really exists, or is it just confounding factors that result in positive 
conclusions (Pistelli et al. 2008). In the majority of the studies on BHR and obesity, 
no significant association has been found (schachter et al. 2001, Aaron 2008, van 
Veen et al. 2008), even though an increased risk for asthma has been presented 
(Schachter et al. 2001). It is common to present that the obese and women, often 
co-presenting as obese women, exhibit a higher prevalance or an increased risk for 
asthma and BHR (Leynaert et al. 2012, Dixon et al. 2010, Shore 2010, Chinn et al. 
2006). As stated by Török and Leuppi (2007) and Kanner et al. (1994), the size of 
airway calibre is an important determinant of BHR. Thus, studies that assess the 
mechanical factors and lung function measurements in association with BHR, both 
in obesity and in subjects with low lung function values (FEV1 and FVC), are required. 
6.1.3.10. Heridity 
Neither parental asthma, nor sibling asthma, increased the risk of BRH in this study 
population. Results of the Italian Po Delta epidemiological study published Kurzius-
Spencer et al. (2004) found a significant father-son correlation of the metacholine 
dose response curve, but no evidence of a major gene causing the BHR itself. 
The genetics studies of BHR have been of minor contribution so far. The linkage 
studies and positional cloning strategies have so far discovered genes, which are 
expressed in epithelial cells and smooth muscle cells (Guy Brussell, personal 
communication, European Respiratory Society Annual Conference, Post Graduate 
course 5, 2011). BHR has been associated with ADAM33, which encodes disintegrin 
and metalloproteinase 33 (Van Eerdewegh et al. 2002), but the genetic background 
of bHr remains unclarified. studies of pooled data bases of blood samples from 
asthmatics and controls are under investigation. 
6.1.4. inciDence Of asthma in finlanD 
Results of the 11years (1996-2007) follow up indicate no further increase the 
incident asthma in Finland. A 4.0% cumulative incidence was evident in this 
general population cohort of 4302 individuals during the years 1996-2007. The 
annual incidence rate of asthma is in line with the results from neighbouring Nordic 
countries (Ekerljung et al. 2008, Torén et al. 2004)(Figure 7). 
Figure 7 illustrates results drawn together from 4 different incident asthma 
studies conducted in Sweden and Finland during the years of 1986-2007. Studies 
included in figure 7 are OLin 1986-1996 (Lundbäck et al. 2001 ), RHINE 1990-
2000 (Torén et al. 2004), FinEsS-Stockholm 1996-2006 (Ekerljung et al. 2008), 
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FinEsS-Helsinki 1996-2007 (Study II) and Huurre et al. 1983-1999 (Huurre et al. 
2004). Data presented are comparable due to the same criteria and same questions 
applied to define population at risk and incident asthma cases.
the first 4 double-bars present numbers for adjusted indicent/ 1000/year among 
men and women, respectively. the studies present a significant gender difference in 
the rates for incident asthma p=0.01, p<0.01, p=0.06, and p=0.026, respectively.
6.1.4.1. Incidence rates 
In Figure 7, the two columns from the right, present incidence rates of asthma in 
two different Finnish cohort studies. Huurre et al. 2004 presents data of 16-32 
years old individuals, where as the age range in the FinEsS-Helsinki cohort was 
20-69 years at the beginning of the study in 1996. In respect to the presented 
incidence rates, the two different finnish asthma studies differ significantly in the 
rate for incidence of asthma, 3.7/1000/ year (FinEsS Hki, Study II) versus 2.1/1000 
/year (Huurre et al. 2004). This could be explained by the difference in the ages 
of studied (20-69 years versus 16-32 years) and by possibly the different years of 
conducting these studies (1996-2007 versus 1983-1999). Both these facts represent 
such determinants, which ought to be taken in consideration when evaluating and 


































black bars refer to men;
gray bars refer to women
white bars refer to crude incident
in men and women  
Figure 7. Incident rates of asthma. (modified from Ekerljung et al. 2008)
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6.1.4.2. Risk factors for incident asthma
The main risk factors for incident asthma have not changed in Finland over the years. 
Heritability and atopy play a major role for incident asthma. In addition to the family 
history of asthma and rhinitis, environmental factors are also strongly contributive, 
including living surroundings and exposure to tobacco smoke. Female gender was 
associated with an increased risk for incidence of asthma. Except for the effect of 
aging, these results are concomitant with the findings of the others’ (ekerljung et 
al. 2008). These results support the actions made worldwide over recent years to 
reduce incidence of allergic and tobacco related diseases (WHOstatement 2002). 
6.2. epiDemiOlOgical cOnsiDeratiOns Of Bhr 
measurements
6.2.1. stuDy cOhOrt anD its effects On final OutcOmes in 
epiDemiOlOgical Bhr stuDies
6.2.1.1. Sample size 
For an epidemiological study setting, the number of individuals included in the 
present studies was small, but acceptable. Some results of the logistic regression 
exhibited a wide 95% CI, but indicated that the result is based on a small number 
of cases, and thus recognizeable while reading and interpreting the results. 
6.2.1.2. Selection
The role of BHR testing in asthma prevalence surveys has been discussed (Pearce 
et al. 2000). It is partly to due the selection procedure for a BHR study, in which 
only individuals that fulfill the inclusion criteria for bHr testing are included, and 
still considered to present a random sample of general population. In addition to 
the reported prevalence of physician diagnosed asthma, other prevalence figures 
are also obviously, more or less, confounded by this selection bias. As this is true 
for all epidemiological studies that include data for bronchial challenge tests, the 
argument is understandable, but not crucial if recognized. 
Another type selection bias results from diversity in anthropometrical data of the 
individuals who are included in a BHR study cohort. A third type of bias considers 
the annual physiological decrement in FEV1 that excludes a certain proportion of 
subjects from BHR follow up studies, and this has not received much attention.
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6.2.1.3. Lung function data at baseline
Most of the BHR-studies reviewed for this thesis have only used the FEV1 predicted 
values, and most of the FEV1 predicted values have been in the normal range. 
However, the absolute baseline FEV1 volumes in an individual level vary a lot, and 
based on results of the present study and others’ (Ulrik 1993 & 1996, Longhini et 
al. 2004), may impact on the evaluation and interfere comparison of the results of 
the inducible bronchoconstriction between different cohorts. 
The baseline FEV1, i.e. airway calibre, has been discussed intermittently since 
the 1980s: Moreno et al. (1986) presented data of smooth muscle contraction 
determined by the variation of the calibre of the bronchus, further Bourbeau et al. 
(1993) studied the anatomical difference of trachea length and diameter in terms of 
deposition effects, and Brusasco & Pellegrino (2003) have published about factors 
modulating airway narrowing. Findings by de Marco et al. (1998) indicated a reduced 
risk for BHR with an increasing baseline FEV1 [L]. In this Italian part of the ECRHS 
I study, risk for BHR was assessed by cut off levels FEV1 3.29 L and 4.08 L, which 
yielded Or 0.45 (95% ci) and Or 0.23 (95% ci 0.1-0.4), respectively, for bHr. 
Functional imaging of the airways and BHR-studies in a longitunal setting may 
provide more information in the future.
6.2.2. statistical analyses in epiDemiOlOgical Bhr stuDies 
6.2.2.1. Continous versus dichotomous variables 
If subjects are excluded from epidemiological BHR studies because of a low 
FEV1-value, had been included in the statistical analyses by recoding them as the 
most severely affected individuals, the results of the logistic regression analysis 
would have benefited from a bigger sample size. this would have increased the 
representativeness of the results, and defined associations and risk factors in a 
more comprehensive way. 
This is true in the longitudinal studies as well, in which subjects are excluded 
due to annual physiological decrement in FEV1. In the case of the presented FinEsS-
Helsinki incident asthma and BHR follow up study, for example, six subjects had 
their baseline FEV1 ≤ 1.75L in 2001-2003, which indicates that with an annual 
25ml physiological decrement in FEV1 these subjects would be excluded from 10-
year follow up measurements because of a low baseline FEV1 value. All these six 
subjects were women, thus causing a drop out in the proportion of women. This 
might subsequently confound some of gender dependent associations.
The logistic regression analysis enables testing of validated cut off levels, and 
provides opportunities to investigate new ones as well, as done in the presented 
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studies (Hosmer & Lemeshow 2000). By categorization of a variable, the problem 
of defining of those subjects who do not present bHr, is overcome. 
6.2.2.2. Dose response slope (DRS) and dose response ratio (DRR) 
Dose response slope (DRS) and dose response ratio (DRR) have been suggested in 
epidemiological studies, where the majority of those studied do not represent BHR 
(Sterk et al. 1985, O’connor 1987, peat et al. 1994). It is common to use a constant 
in the calculation of DRS that might cause some bias for the BHR. As published 
by Curjuric et al. (2011), a change in the slope might present a more informative, 
realiable, and suitable method for presenting data in an epidemiological setting. 
6.2.2.3. different Fev1 response limits
In general, different FEV1 response limits can be used in bronchial challenge tests, 
but the use of higher FEV1 response limits necessitates the use of higher doses of 
constrictors. In a population with mild airway responsiveness, lower FEV1 cut-
off levels have been suggested (Michoud et al. 1982, Neijens et al. 1982, Popa & 
Singleton 1988, Fardon et al. 2004). Investigation of an absolute FEV1 decrement 
gives a real picture of the change in the induced flow limitation, such as the exercise 
induced bronchoconstriction (EIB), and might be useful in evaluation of sub-
maximal responses of airway obstruction and perception of dyspnea. 
6.2.2.4. PD15 / PD20 FEV1
Methods based on the PD15/20FEV1 values provide quantative data of BHR. New 
research data as defined in pD-values are implicated to the clinical praxis without 
conversions, and the PD15/20FEV1 values can be individually followed in a longitudinal 
setting in taking care of a patient. 
Intra-individual variation in PD values of histamine vs. methacholine, as a 
limitation, could be explained by differences in the position and form of the dose-
response curves of FEV1 to histamine and methacholine. The curves are typically 
more sigmoid than linear, which hinders the procurement of repeatable PD results 
for less hyperreactive subjects (Woolcock et al. 1984, Sterk et al. 1985, Lougheed 




6.2.3. Bhr in a lOngituDinal setting
6.2.3.1. Baseline measurements of BHR in childhood and follow up 
bHr is commonly assessed in addition to replies of respiratory symptoms in defining 
asthma or respiratory illness (Rasmussen et al. 1999, Kotaniemi-Syrjänen et al. 
2007, Meren et al. 2005, Chinn et al. 2007). In children 5-10 years of age, FEV1 
measurements during a challenge test could be applied (Malmberg et al. 2001). 
Spirometry could be recommened from 7-9 years of age onwards, and it is propably 
the most commonly used measurement of ventilation from then on (Escobar & 
Carver 2011). However, representativiness of the spirometry measurements should 
be carefully evaluated (Malmberg et al. 2001), and measurements that do not fulfill 
the ATS/ ERS criteria (Pellegrino et al. 2005) for repeatability by a single measure 
or by the three comparable curves due to a lack of co-operation, should absolutely 
be excluded from the analysis. The baseline measurements are the most critical in 
the longitudinal setting. 
new pulmonary lung function techniques, such as impulse oschillometry (iOs), 
give comparable results to the spirometric values (Goldman et al. 2002, Houghton 
et al. 2004, Evans et al. 2005), thus could be considered in younger and less co-
operative individuals (Escobar & Carver 2011, Shi et al. 2012). 
6.2.3.2. BHR and incident asthma in longitudinal studies
there is no golden standard to measure and define the abnormally increased 
BHR, which make the comparison of different epidemiogical studies more or less 
unreliable in terms of incidence of asthma. However, an equal criterion for the 
population at risk enables the assessment and comparison of new asthma cases 
between different studies. 
The ERS and ATS task forces could publish clinically validated BHR cut off levels 
in terms of follow-up instructions for abnormally increased BHR. Evidence of BHR 
as an independent determinant for incident respiratory symptoms, lung function 
decrement, and incident asthma, exist based on reports from the SAPALDIA-, 
ECRHS I and II – studies (Jansen et al. 1997, de Marco et al. 1998, Janson et 
al. 2001, Schwartz et al. 2002, Chinn et al. 1997 & 2007, Brutsche et al. 2006, 
Curjuric et al. 2011).
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7 suMMary oF results and conclusions
the main results Of the thesis
1. Histamine PD15FEV1 and methacholine PD20FEV1 methods have a good 
agreement in assessment of BHR severity among subjects without physician 
diagnosed asthma or chronic bronchitis.
 
2. The prevalence of BHR in subjects without physician diagnosed asthma 
assessed by the histamine test (PD15FEV1 ≤ 1.6 mg) was 28%, and by the 
methacholine test  (PD20FEV1 ≤ 2.6 mg) was 20%, in kemi. 
3. Prevalence of bHr defined as histamine pD15FEV1 ≤ 1.6 mg was 21% in 
the general adult population in Helsinki. Prevalence of moderate or severe 
bHr (bHrms) defined as  histamine pD15FEV1 ≤ 0.4 mg was 6% in the 
Helsinki adult population. 
4. The main risk factor for BHR was decreased FEV1; showing a five-fold risk 
for BHR and a 14-fold risk for BHRms.
 Decreased MEF50 increased the risk for BHR and BHRms by 7- to 17- fold, 
respectively.
5. Of the subjects with BHR 69 % were ever smokers, and 32% current smokers. 
For BHRms the percentages were 83% and 56%, respectively.
 BHR was dose dependently associated with pack years of smoking. 
 Exposure to environmental tobacco smoke (ETS) at work was a risk factor 
for BHR. 
6. Allergic constitution was not significantly associated with bHr in the general 
adult population. Atopy combined with obstruction yielded a six-fold risk 
for BHR. 
 Subjects tested during pollen season presented a higher risk for BHR than 
subjects tested outside the season.
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7 Summary of results and conclusions
 Multisensitization (positive skin prick test at least for six allergens) yielded 
a four-fold risk for BHRms.
 Obesity (BMI>30 kg/m2) was not significantly associated with bHr.
7. Exhaled nitric oxide (fenO) leveled the bHr severity only among the non-
smokers.
8. The incidence of asthma was 3.7/1000 persons/year.
 Remission of asthma was 17% during the follow up of 11 years. 
 Allergic rhinitis doubled the risk for incident asthma, whereas living in a 
farm below five years of age reduced the risk for incident rhinoconjunctivitis.
conclusions
BHR carries a remarkable role in the dynamic changes of lung function in the 
general adult population in Helsinki. One in five of the studied subjects presented 
BHR, and among ever smokers BHRms comprised in a four-folded magnitude. 
the findings suggest that the occurence of non-specifc bHr assessed by histamine 
is associated with several environmental and individual risk factors affecting the 
smooth muscle response in the airway. 
Results of the present studies indicate that decreased ventilatory function, due to 
large or small airway obstruction, is the most essential determinant for BHR. This 
is probably due to the disturbed airway function and heterogeneity in ventilation 
typically found in asthmatic conditions or in chronic obstructive pulmonary disease. 
The correlation of BHR to MEF50 supports the view of using BHR in the evaluation 
of small airway disease. 
The results presented here revealed that smoking was an independent risk 
factor for bHr and bHrms in a dose-dependent manner. Of the ever smokers, 
the majority had started to smoke before the age of 20 years. Exposure to tobacco 
smoke in assessment of increased bHr in adulthood should be notified in planning 
anti-smoking actions worldwide. 
allergic consititution by itself was not a significant determinat of bHr in the adult 
general population. Our results are in line with the point of view that non-allergic 
conditions of the united airways, such as rhinits and remodelling changes of the 
airway epithelium, play an increasing role in respiratory diseases and symptoms in 
adulthood as recently reported by others. The determinants of BHR show a different 
pattern of risk factors with different ages. 
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Multiple positive reactions in the skin prick tests (multisensitization) increased 
the risk for bHrms, which is probably linked to eosinophilic inflammation in the 
airways typically seen in the corticosteroid-dependent eosinophilic asthma. The 
correlation of increased fenO and bHr among non-smokers only, reported in 
this study to date, supports this deduction.
By a direct dosimetric method, BHR could be objectively measured. BHR should 
be evaluated in the assessment of respiratory symptoms if spirometry is normal 
as stated in the asthma guidelines (GINA, the Finnish Asthma Guideline). These 
results indicate that ever smokers and subjects with multisensitization are easily 
recommended for BHR testing. Allergic rhinoconjunctivitis was not associated with 
increased BHR, although ARC resulted as one of the main risk factors for adult 
onset asthma during an 11-year follow up. 
Finally, methodological aspects such as the assessment of low FEV1 value in 
terms of BHR severity, gender, and obesity could be considerated for further general 
population studies of BHR. From the clinical point of view, BHR targeted treatment 
trials, could provide a new approach for the evaluation of the effectiveness of new 
anti-inflammatory and anti-cholinergic drugs in chronic respiratory symptoms 
and diseases. new technology will enable the use of risk profile calculations for 
respiratory events, and such models could provide calculation frames for evaluation 
of cost effectiveness of BHR’s position in evalution and tretament of respiratory 
symptoms and diseases.
The issue of BHR is complex. Findings of this thesis suggest that quantitative 
assessment of BHR by different cut off levels provides a tool for characterization 
of phenotypes of airway disorders in epidemiological studies. It is challenge for all 
physicians to implicate all of the available pathophysiological and epidemiological 
data in our clinical work. 
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APPENDIX I FinEsS-tutkimus 2007
Merkitse seuraavissa kysymyksissä rasti mielestäsi sopivien vaihtoehtojen kohdalle!
(siis jokaiseen kysymysvaihtoehtoon joko kyllä tai ei/en tiedä)
Kyllä Ei / En tiedä
a) astmaa (  ) (  )
(  ) (  )
(  ) (  )
a) astmaa (  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
060619
  Jos vastasit kyllä:  Minkä ikäinen olit kun astma todettiin?                    vuotta
6. Onko Sinulla ollut astmaoireita nykyisin tai viimeisten 10 vuoden aikana ? (ajoittain 
hengenahdistusta tai hengenahdistuskohtauksia, samanaikaisesti voi olla yskää tai hengityksen 
vinkumista)
  Jos vastasit kyllä: 
  Jos vastasit kyllä: 
5. Käytätkö astmalääkkeitä ? Mitä lääkettä:
a) Onko sinulla ollut astmaoireita viimeisten 12 kuukauden aikana ?
  Jos vastasit kyllä: 
8. Nouseeko yskiessä keuhkoistasi yleensä limaa tai onko keuhkoissa limaa, jota on vaikea saada 
irtoamaan ?
b) onko tällaisia vähintään kolmen kuukauden limannousujaksoja ollut vähintään kahtena 
peräkkäisenä vuonna?
9. Onko tavallista, että keuhkoissa hengityksesi rahisee äänekkäästi tai vinkuu ?
10. Onko sinulla ollut hengityksen vinkunaa kertaakaan viimeisten  12 kuukauden aikana ?
7. Onko Sinulla ollut viime vuosina pitkäaikaista yskää ?
a) onko limaa noussut useimpina päivinä vähintään kolmen peräkkäisen kuukauden aikana?
3. Onko lääkäri todennut Sinulla olevan astmaa ?
4. Onko lääkäri todennut Sinulla olevan kroonista (pitkäaikaista) keuhkoputkentulehdusta, 
keuhkoahtaumatautia tai keuhkonlaajentumaa?
1. Onko jollakin vanhemmistasi tai sisaruksistasi ?
b) allergista nuhaa (esim. heinänuhaa) tai allergista silmävaivaa
c) kroonista keuhkoputkentulehdusta, keuhkoahtaumatautia tai keuhkonlaajentumaa
2. Onko Sinulla nyt tai onko Sinulla ollut aiemmin ?
b) allergista nuhaa (esim. heinänuhaa) tai allergista silmävaivaa
c) kroonista keuhkoputkentulehdusta, keuhkoahtaumatautia tai keuhkonlaajentumaa
d) muu keuhko- tai hengityselinsairaus, mikä ?
kirjoita vastaus tähän:
11. Oletko viimeisten 12 kuukauden aikana herätessäsi kertaakaan kokenut hengityksesi olevan 
tukossa?
Nimi:
a) oliko Sinulla ollenkaan hengenahdistusta vinkunan yhteydessä ?
b) oliko Sinulla hengityksen vinkunaa vaikka et ollut flunssassa ?
12. Hengästytkö tai joudutko hengästymisen vuoksi kävelemään hitaammin kuin muut, kun kävelet 
ikäistesi henkilöiden kanssa tasamaalla normaalivauhdilla?
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Kyllä Ei / En tiedä
a) rasituksessa (  ) (  )
b) kylmässä (  ) (  )
c) pakkasessa rasituksen yhteydessä (  ) (  )
d) pölyisissä olosuhteissa (  ) (  )
e) tupakansavusta (  ) (  )
f) autojen pakokaasuista (  ) (  )
(  ) (  )
h) kasvien tai puiden siitepölyistä (  ) (  )
i) ollessasi tekemisissä eläinten kanssa (  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
(  ) (  )
Vastaukset kerätään tutkimusrekisteriin Filha Ry, Sibeliuksenkatu 11 A1, 00250 Helsinki, 09-45421265
ja Keuhkosairauksien tutkimusyksikköMeilahden sairaala, HYKS, Haartmaninkatu 4, PL 340, 00029 HUS, p 09-4711
060619
Allekirjoitus:
21. Asuitko maaseudulla (ei kaupungissa eikä taajamassa)  ensimmäisten 5 elinvuotesi aikana?
18. Onko työympäristössäsi nyt tai onko työympäristössäsi ollut aikaisemmin paljon pölyä, kaasuja 
tai savua?
19. Mikä on pituutesi ja painosi?:                      cm                      kg
a) Asuitko maatilalla ensimmäisten 5 elinvuotesi aikana?
         a) noussut                      kg / laskenut                        kg
22. Onko terveydentilassasi tapahtunut jokin merkittävä muutos viimeisen 10 vuoden aikana?
Päiväys:                                                     Puhelinnumerosi:
17. Onko Sinulla nykyisin muu työ tai tehtävä (muu ammatti, opiskelu, työtön, kotityö, eläke, 
sairauseläke tms.)?
jos on niin mikä?, kirjoita vastaus tähän:
a) montako vuotta olet yhteensä ollut tässä työssä, eläkkeellä, tms.:                        vuotta
b) Oletko aiemmin ollut tupakoitsija, mutta lopetit yli vuosi sitten?
         a) Minkä ikäisenä lopetit?                       vuotiaana
15. Jos olet tai olet ollut tupakoitsija minkä ikäisenä aloitit?                           vuotiaana
         a) minä vuosina olet ollut tässä työssä? vuodesta                         vuoteen
Tarkenna jos vastasit kyllä:
20. Kuinka paljon painosi on muuttunut kymmenen vuoden aikana?
13. Saatko hengenahdistusta, hengityksen vinkunaa tai vaikeita yskänpuuskia?
g) voimakkaista tuoksuista (esim. deodorantit, mausteet, 
painomuste, puhdistusaineet, kukkien tuoksut tms.)
16. Missä ammatissa olet pääasiassa toiminut? Kirjoita vastaus tähän:
                                                                  d) vähintään 25 kpl
14. Poltatko savukkeita, sätkää, piippua tai sikareita? (vastaa kyllä vaikka olisitkin lopettanut 
viimeisten 12 kuukauden aikana)
  Jos vastasit ei: 
a) Kuinka monta savuketta, sätkää, sikaria tai piipullista olet
    polttanut keskimäärin vuorokaudessa ? a) vähemmän kuin 5 kpl
                                                                  b) 5-14 kpl
                                                                  c) 15-24 kpl
  Jos vastasit kyllä: 
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APPENDIX II          FinEsS-studien 2007  
Namn: 
 
Besvara frågorna genom att kryssa för ett lämpligt alternativ. 
(besvara varje fråga antingen med JA eller NEJ / VET EJ) 
 
1. Är det någon av Dina föräldrar eller syskon som har?    JA NEJ / VET EJ 
 
a) astma          (   )  (   ) 
b) allergisk snuva (t.ex hösnuva) eller allergiska ögonbesvär    (   )  (   ) 
c) kronisk luftrörskatarr, kronisk obstruktiv lungsjukdom eller emfysem  (   )  (   ) 
2. Har Du nu eller har Du tidigare haft? 
 
a) astma          (   )  (   ) 
b) allergisk snuva (t.ex hösnuva) eller allergiska ögonbesvär   (   )  (   ) 
c) kronisk luftrörskatarr, kronisk obstruktiv lungsjukdom eller emfysem  (   )  (   ) 
d) annan lung- eller luftvägssjukdom, vilken? ________________________ 
3.  Har Du av läkare fått diagnosen astma?      (   )  (   ) 
 
Om Du svarade ja: Hur gammal var Du då astman konstaterades? ______ år 
 
4.   Har Du av läkare fått diagnosen kronisk (långvarig) luftrörskatarr (bronkit), 
kronisk obstruktiv lungsjukdom eller emfysem?     (   )  (   )  
 
5.   Använder Du astmamediciner? Vilka läkemedel? ___________________  (   )  (   ) 
 
 
6.  Har Du nu eller har Du under de senaste 10 åren haft astmasymptom?  (   )  (   ) 
     (periodvis andnöd eller andnödsanfall,  besvären kan uppträda med 
     samtidig hosta  eller pip i bröstet) 
 
Om Du svarade ja: 
      a) Har Du haft astmasymptom under de senaste 12 månaderna?   (   )  (   ) 
 
7.  Har Du under de senaste åren haft långvarig hosta?     (   )  (   ) 
 
8. Brukar Du hosta upp slem eller har Du slem i lungorna, vilket är svårt  att få upp? (   )  (   ) 
          
Om Du svarade ja: 
       a) Har Du fått upp slem de flesta dagar under en period som varat minst 3 månader (   )  (   ) 
       b) Har Du haft sådana 3 månaders perioder minst 2 år i rad?   (   )  (   ) 
 
9. Brukar Dina lungor rossla hörbart eller brukar din andning pipa?   (   )  (   ) 
 
10. Har Du haft pip i bröstet vid något tillfälle under de senaste 12 månaderna?  (   )  (   ) 
Om Du svarade ja: 
      a) Har Du överhuvudtaget varit det minsta andfådd när Du haft pip i bröstet?  (   )  (   ) 
      b) Har Du haft pip i bröstet utan att samtidigt vara förkyld?    (   )  (   ) 
 
11. Har Du vaknat med trånghetskänsla i bröstet vid något tillfälle under de  
     senaste12 månaderna?        (   )  (   ) 
 
12. Blir Du andfådd eller måste Du gå långsammare än jämnåriga på plan mark i 
     normal takt på grund av andfåddhet?       (   )  (   ) 
 
          060619 
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13. Får Du andnöd, pip i bröstet eller svåra hostattacker?    JA      NEJ / VET EJ 
 a) vid ansträngning        (   )  (   ) 
 b) i kyla          (   )  (   ) 
 c) vid ansträngning utomhus i kallt väder      (   )  (   ) 
 d) i dammiga miljöer        (   )  (   ) 
 e) av tobaksrök         (   )  (   ) 
 f) av bilavgaser         (   )  (   ) 
 g) av starka dofter         (   )  (   ) 
(deodoranter, kryddor, trycksvärta, rengöringsmedel, blomsterdoft osv) 
h) av pollen från växter eller träd      (   )  (   ) 
i) i kontakt med djur        (   )  (   ) 
14. Röker Du cigaretter, handrullade cigaretter, pipa eller cigarrer?    (   )  (   ) 
      (svara ja även ifall Du slutat röka inom de senaste 12 månaderna) 
Om Du svarade ja: 
 a) Hur många cigaretter, handrullade cigaretter, cigarrer eller pipstopp ha Du rökt 
 i medeltal per dygn  a) mindre  än 5 st     (   ) 
    b) 5 – 14 st      (   ) 
    c) 15 –24 st      (   ) 
    d) minst 25 st      (   ) 
Om Du svarade nej: 
 b) Har Du tidigare varit rökare men slutat för mer än 1 år sedan?   (   )  (   ) 
 
15. Om Du är eller har varit rökare, i vilken ålder började Du röka? Som ________-åring 
a) I vilken ålder slutade Du röka? Som ________-åring 
16. Vilket har varit Ditt huvudsakliga yrke? ____________________________________ 
a) Hur många år har Du varit i detta yrke? Från år ________ till år __________ 
17. Är Du nu i någon annan verksamhet / sysselsättning      (   )  (   ) 
(annat yrke, studier, arbetslös, hemarbete, pensionär, sjukpensionär o. dyl.)? 
Om Du svarade ja: vilket? ________________________________________ 
a) Hur många år har Du sammalagt varit i denna verksamhet, pensionär el. dyl. 
____________år 
18. Finns det nu eller har det tidigare funnits mycket damm, gaser eller rök i 
      Din arbetsmiljö?         (   )  (   ) 
 
19. Vad är Din längd och Din vikt? __________cm  ___________kg 
 
20. Hur mycket har Din vikt förändrats de senaste 10 åren? 
a) ökat ________kg / minskat ________kg 
21. Bodde Du på landsbygden (inte i stad eller tätort) under Dina 5 första levnadsår? (   )  (   ) 
 a) Bodde du på en lantgård under Dina 5 första levnadsår?   (   )  (   ) 
 
22.  Har det skett någon väsentlig förändring i Ditt hälsotillstånd under de senaste 10 åren? 
           (   )  (   ) 
 
Precisera om Du svarade ja:_______________________________________________ 
 
 
Datum:__________________________ Ditt telefonnummer:_______________________ 
 
Underskrift:__________________________________________                                                                           
060619 
 
Svaren samlas i forskningsregister vid Filha ry, Sibeliusgatan 11 A1, 00250 Helsinki, puh 09-45421265, och 
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